Parathyroid hyperplasia is enlargement of parathyroid tissue due to increased parathyroid cellular mass. It can occur as multiglandular disease in primary hyperparathyroidism, as CKD-driven secondary hyperparathyroidism, or as autonomous tertiary hyperparathyroidism after prolonged stimulation.
Ask a research question about Parathyroid Hyperplasia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Parathyroid Hyperplasia:
name: Parathyroid Hyperplasia
creation_date: "2026-05-07T23:30:03Z"
updated_date: "2026-05-08T00:08:30Z"
category: Complex
description: >-
Parathyroid hyperplasia is enlargement of parathyroid tissue due to increased
parathyroid cellular mass. It can occur as multiglandular disease in primary
hyperparathyroidism, as CKD-driven secondary hyperparathyroidism, or as
autonomous tertiary hyperparathyroidism after prolonged stimulation.
synonyms:
- Hyperplasia of parathyroid
- Parathyroid gland hyperplasia
- Multiglandular parathyroid disease
- Four-gland hyperplasia
disease_term:
preferred_term: parathyroid hyperplasia
term:
id: MONDO:0006354
label: parathyroid hyperplasia
parents:
- Parathyroid Gland Disorder
- Hyperplasia
has_subtypes:
- name: Primary MGD
display_name: Primary hyperparathyroidism-associated multiglandular disease
description: >-
Multiglandular parathyroid disease in primary hyperparathyroidism, often
enriched among hereditary presentations and relevant to surgical planning.
evidence:
- reference: DOI:10.1210/endrev/bnad009
reference_title: Molecular and Clinical Spectrum of Primary Hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Genetic testing for heritable forms should be offered to patients with
multiglandular disease, recurrent PHPT, young onset PHPT (age ≤40 years),
and those with a family history of parathyroid tumors.
explanation: >-
The review identifies multiglandular disease as a clinically important
PHPT presentation that should prompt hereditary evaluation.
- name: Secondary SHPT
display_name: CKD-related secondary parathyroid hyperplasia
description: >-
Compensatory parathyroid hyperplasia in chronic kidney disease, driven by
disordered calcium-phosphate-vitamin D physiology and persistently elevated
parathyroid hormone.
evidence:
- reference: DOI:10.3390/medicina60050812
reference_title: "Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Secondary hyperparathyroidism (SHPT) poses a common condition among
patients with chronic kidney disease (CKD) due to the chronic stimulation
of the parathyroid glands as a result of persistently low calcium levels.
explanation: >-
This directly supports CKD-related chronic parathyroid stimulation as a
secondary hyperplasia context.
- name: Tertiary HPT
display_name: Tertiary hyperparathyroidism
description: >-
Autonomous hyperparathyroidism after prolonged secondary hyperparathyroidism,
commonly involving multiple glands and often considered in kidney transplant
settings.
evidence:
- reference: DOI:10.5772/intechopen.1006528
reference_title: "What Is the Role of Surgery in Secondary and Tertiary Hyperparathyroidism?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
THPT often involves multiple glands, adversely affecting bone metabolism,
cardiovascular risk, and kidney allograft function, thus warranting PTx.
explanation: >-
Supports multiglandular autonomous disease as a tertiary
hyperparathyroidism presentation.
inheritance:
- name: Autosomal Dominant
inheritance_term:
preferred_term: autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
description: >-
Hereditary primary hyperparathyroidism syndromes associated with
multiglandular disease are often autosomal dominant, but sporadic and
CKD-related forms are not inherited as single-gene traits.
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primary hyperparathyroidism (PHPT), a relatively common disorder
characterized by hypercalcemia with raised or inappropriately normal serum
parathyroid hormone (PTH) concentrations, may occur as part of a
hereditary syndromic disorder or as a non-syndromic disease.
explanation: >-
Supports the distinction between hereditary syndromic and non-syndromic
PHPT contexts.
pathophysiology:
- name: Parathyroid Cellular Hyperplasia
description: >-
Expansion of parathyroid gland cellular mass increases the glandular
capacity for parathyroid hormone production and secretion. In primary
hyperparathyroidism, multiglandular disease is an important surgical and
genetic subtype.
biological_processes:
- preferred_term: cell population proliferation
term:
id: GO:0008283
label: cell population proliferation
- preferred_term: parathyroid hormone secretion
term:
id: GO:0035898
label: parathyroid hormone secretion
evidence:
- reference: DOI:10.1210/endrev/bnad009
reference_title: Molecular and Clinical Spectrum of Primary Hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
PHPT is associated with morbidities (fractures, kidney stones, chronic
kidney disease) and increased risk of death.
explanation: >-
Links primary parathyroid hormone excess to downstream renal and skeletal
morbidity.
downstream:
- target: Calcium Homeostasis Disruption
description: Excess parathyroid hormone output disrupts calcium homeostasis.
causal_link_type: DIRECT
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primary hyperparathyroidism (PHPT), a relatively common disorder
characterized by hypercalcemia with raised or inappropriately normal
serum parathyroid hormone (PTH) concentrations, may occur as part of a
hereditary syndromic disorder or as a non-syndromic disease.
explanation: >-
Defines the biochemical pattern of PHPT as hypercalcemia with raised or
inappropriately normal PTH.
- name: CKD-Driven Secondary Parathyroid Stimulation
description: >-
Chronic kidney disease alters calcium, phosphate, and vitamin D balance,
chronically stimulating the parathyroid glands and producing secondary
hyperparathyroidism with gland enlargement.
biological_processes:
- preferred_term: calcium ion homeostasis
term:
id: GO:0055074
label: calcium ion homeostasis
- preferred_term: parathyroid hormone secretion
term:
id: GO:0035898
label: parathyroid hormone secretion
modifier: INCREASED
evidence:
- reference: clinicaltrials:NCT01421407
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
sHPT is characterized by persistently elevated levels of parathyroid
hormone (PTH) and major disturbances in phosphorus and calcium metabolism.
explanation: >-
The trial summary directly describes the biochemical pattern of secondary
hyperparathyroidism.
downstream:
- target: SHPT Glandular Autonomy
description: >-
Persistent secondary hyperparathyroidism can become refractory and raise
concern for glandular autonomy.
causal_link_type: DIRECT
evidence:
- reference: DOI:10.5772/intechopen.1006528
reference_title: "What Is the Role of Surgery in Secondary and Tertiary Hyperparathyroidism?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Refractory sHPT, unresponsive to pharmacological treatments,
necessitates an individualized approach to parathyroidectomy (PTx).
explanation: >-
Supports refractory secondary hyperparathyroidism as a clinically
important progression state after chronic parathyroid stimulation.
- name: SHPT Glandular Autonomy
description: >-
Longstanding CKD-related secondary hyperparathyroidism can progress to a
refractory autonomous state that overlaps tertiary hyperparathyroidism and
often requires surgical management.
biological_processes:
- preferred_term: parathyroid hormone secretion
term:
id: GO:0035898
label: parathyroid hormone secretion
modifier: INCREASED
evidence:
- reference: DOI:10.5772/intechopen.1006528
reference_title: "What Is the Role of Surgery in Secondary and Tertiary Hyperparathyroidism?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
When glandular autonomy is suspected, the timing of PTx ideally precedes
kidney transplantation.
explanation: >-
Supports glandular autonomy as a management-relevant state in the
secondary-to-tertiary hyperparathyroidism spectrum.
downstream:
- target: Tertiary Hyperparathyroid Skeletal and Renal Morbidity
description: >-
Autonomous tertiary hyperparathyroidism affects bone metabolism,
cardiovascular risk, and kidney allograft function.
causal_link_type: DIRECT
evidence:
- reference: DOI:10.5772/intechopen.1006528
reference_title: "What Is the Role of Surgery in Secondary and Tertiary Hyperparathyroidism?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
THPT often involves multiple glands, adversely affecting bone
metabolism, cardiovascular risk, and kidney allograft function, thus
warranting PTx.
explanation: >-
Connects autonomous tertiary hyperparathyroidism to downstream skeletal,
cardiovascular, and renal allograft morbidity.
- name: Transcriptional Heterogeneity in Parathyroid Tumors
description: >-
Sporadic parathyroid tumors show heterogeneous transcriptomic programs
involving MEN1, CDC73, GCM2, CASR, VDR, CCND1, and CDKN1B, which may
contribute to clinical and biochemical variability.
biological_processes:
- preferred_term: epigenetic regulation of gene expression
term:
id: GO:0040029
label: epigenetic regulation of gene expression
- preferred_term: negative regulation of apoptotic process
term:
id: GO:0043066
label: negative regulation of apoptotic process
evidence:
- reference: DOI:10.3390/ijms251910782
reference_title: Heterogeneous Transcriptional Landscapes in Human Sporadic Parathyroid Gland Tumors
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Based on a gene set including MEN1, CDC73, GCM2, CASR, VDR, CCND1, and
CDKN1B, the transcriptomic profiles were analyzed using a cluster analysis.
explanation: >-
Supports use of these genes as a molecular framework for parathyroid tumor
heterogeneity.
downstream:
- target: Calcium Homeostasis Disruption
description: >-
Transcriptional heterogeneity in parathyroid tumors may modulate clinical
and biochemical features.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: DOI:10.3390/ijms251910782
reference_title: Heterogeneous Transcriptional Landscapes in Human Sporadic Parathyroid Gland Tumors
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In conclusion, PAds display heterogeneous transcriptomic profiles which
may contribute to the modulation of clinical and biochemical features.
explanation: >-
Supports a downstream link from transcriptional heterogeneity to
clinical and biochemical variability in parathyroid adenomas.
phenotypes:
- name: Parathyroid Hyperplasia
description: Hyperplasia or enlargement of the parathyroid glands.
phenotype_term:
preferred_term: Parathyroid hyperplasia
term:
id: HP:0008208
label: Parathyroid hyperplasia
evidence:
- reference: clinicaltrials:NCT01421407
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
HIFU may become a valuable alternative treatment that help control
secondary hyperparathyroidism in selected patients presenting with enlarged
parathyroid gland(s) visible at ultrasonography,.
explanation: >-
The trial summary ties secondary hyperparathyroidism to enlarged
parathyroid glands visible on ultrasound.
- name: Hypercalcemia
description: Increased circulating calcium concentration.
phenotype_term:
preferred_term: Hypercalcemia
term:
id: HP:0003072
label: Hypercalcemia
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primary hyperparathyroidism (PHPT), a relatively common disorder
characterized by hypercalcemia with raised or inappropriately normal serum
parathyroid hormone (PTH) concentrations, may occur as part of a
hereditary syndromic disorder or as a non-syndromic disease.
explanation: >-
Defines hypercalcemia as part of the biochemical phenotype of PHPT.
- name: Elevated Parathyroid Hormone
description: Increased circulating parathyroid hormone concentration.
phenotype_term:
preferred_term: Elevated circulating parathyroid hormone level
term:
id: HP:0003165
label: Elevated circulating parathyroid hormone level
evidence:
- reference: clinicaltrials:NCT01421407
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
sHPT is characterized by persistently elevated levels of parathyroid
hormone (PTH) and major disturbances in phosphorus and calcium metabolism.
explanation: >-
Directly supports elevated PTH as the defining biochemical abnormality in
secondary hyperparathyroidism.
- name: Nephrolithiasis
description: Kidney stone formation associated with hyperparathyroid states.
phenotype_term:
preferred_term: Nephrolithiasis
term:
id: HP:0000787
label: Nephrolithiasis
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Syndromic PHPT tends to be multifocal and multiglandular with most
patients requiring parathyroidectomy with the aim of limiting end-organ
damage associated with hypercalcemia, particularly osteoporosis,
nephrolithiasis, and renal failure.
explanation: >-
Supports nephrolithiasis as a clinically important end-organ complication
of syndromic multiglandular PHPT.
- name: Osteoporosis
description: Reduced bone mineral density due to excess parathyroid hormone activity.
phenotype_term:
preferred_term: Osteoporosis
term:
id: HP:0000939
label: Osteoporosis
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Syndromic PHPT tends to be multifocal and multiglandular with most
patients requiring parathyroidectomy with the aim of limiting end-organ
damage associated with hypercalcemia, particularly osteoporosis,
nephrolithiasis, and renal failure.
explanation: >-
Supports osteoporosis as an end-organ complication targeted by treatment
in syndromic multiglandular PHPT.
- name: Increased Susceptibility to Fractures
description: Fracture morbidity associated with primary hyperparathyroidism and skeletal fragility.
phenotype_term:
preferred_term: Increased susceptibility to fractures
term:
id: HP:0002659
label: Increased susceptibility to fractures
evidence:
- reference: DOI:10.1210/endrev/bnad009
reference_title: Molecular and Clinical Spectrum of Primary Hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
PHPT is associated with morbidities (fractures, kidney stones, chronic
kidney disease) and increased risk of death.
explanation: >-
Supports fracture morbidity as a clinically central manifestation of
primary hyperparathyroidism.
- name: Renal Osteodystrophy
description: Skeletal complication of CKD-related secondary hyperparathyroidism.
phenotype_term:
preferred_term: Renal osteodystrophy
evidence:
- reference: DOI:10.5772/intechopen.1006528
reference_title: "What Is the Role of Surgery in Secondary and Tertiary Hyperparathyroidism?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Secondary hyperparathyroidism (sHPT) contributes significantly to renal
osteodystrophy, cardiovascular morbidity, and mortality.
explanation: >-
Supports renal osteodystrophy as a complication of CKD-related secondary
hyperparathyroidism. No ontology binding is included because local OAK
verification showed the reviewer-suggested HP:0003338 label does not
correspond to renal osteodystrophy.
- name: Bone Pain
description: Bone pain can accompany persistent symptomatic secondary hyperparathyroidism.
phenotype_term:
preferred_term: Bone pain
term:
id: HP:0002653
label: Bone pain
evidence:
- reference: DOI:10.5772/intechopen.1006528
reference_title: "What Is the Role of Surgery in Secondary and Tertiary Hyperparathyroidism?"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
PTx in refractory sHPT should be considered when parathyroid hormone
levels progressively rise or sHPT-related symptoms persist.
explanation: >-
Supports persistent symptoms in refractory secondary hyperparathyroidism;
the cached abstract does not specify frequency or enumerate individual
pain symptoms, so this is partial support for bone pain.
- name: Gastrointestinal Symptoms
description: Gastrointestinal symptoms reported in clinically severe primary hyperparathyroid lesions.
phenotype_term:
preferred_term: Abdominal pain
term:
id: HP:0002027
label: Abdominal pain
evidence:
- reference: DOI:10.3389/fendo.2023.1027598
reference_title: Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a Chinese cohort
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Less bone involvement and gastrointestinal symptoms were presented in APA
compared to PC (35.4% vs. 62.0%, and 17.7% vs. 41.8%), while more
urolithiasis was seen in APA than in benign lesions (57.0% vs. 29.6%).
explanation: >-
Supports gastrointestinal symptoms in parathyroid neoplasia cohorts that
overlap clinically severe PHPT presentations; the HPO binding uses the
closest locally verified abdominal symptom term.
- name: Chronic Kidney Disease
description: Chronic kidney disease can be both a driver of secondary hyperplasia and a morbidity of PHPT.
phenotype_term:
preferred_term: Chronic kidney disease
term:
id: HP:0012622
label: Chronic kidney disease
evidence:
- reference: DOI:10.1210/endrev/bnad009
reference_title: Molecular and Clinical Spectrum of Primary Hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
PHPT is associated with morbidities (fractures, kidney stones, chronic
kidney disease) and increased risk of death.
explanation: >-
Supports chronic kidney disease as a morbidity associated with primary
hyperparathyroidism.
genetic:
- name: MEN1-associated hereditary PHPT
gene_term:
preferred_term: MEN1
term:
id: hgnc:7010
label: MEN1
association: Predisposing
subtype: Primary MGD
features: >-
MEN1-related PHPT is a hereditary syndromic form in which parathyroid
involvement is commonly multifocal or multiglandular.
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The associated syndromic disorders include multiple endocrine neoplasia
types 1–5 (MEN1-5) and hyperparathyroidism with jaw tumor (HPT-JT)
syndromes, and the non-syndromic forms include familial hypocalciuric
hypercalcemia types 1–3 (FHH1-3), familial isolated hyperparathyroidism
(FIHP), and neonatal severe hyperparathyroidism (NS-HPT).
explanation: >-
Supports MEN1-spectrum syndromes among hereditary PHPT disorders.
- name: CDC73-associated hereditary PHPT
gene_term:
preferred_term: CDC73
term:
id: hgnc:16783
label: CDC73
association: Predisposing
subtype: Primary MGD
features: >-
CDC73 variants cause hyperparathyroidism-jaw tumor syndrome and can be
relevant in familial primary hyperparathyroidism and atypical or malignant
parathyroid lesions.
evidence:
- reference: DOI:10.3389/fendo.2023.1027598
reference_title: Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a Chinese cohort
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Germline CDC73 mutation was the most common molecular abnormality in both
PC and APA subjects.
explanation: >-
Supports CDC73 as a recurrent germline abnormality in clinically severe
parathyroid neoplasia overlapping PHPT presentations.
- name: CASR-related familial hypocalciuric hypercalcemia differential
gene_term:
preferred_term: CASR
term:
id: hgnc:1514
label: CASR
association: Differential Diagnosis
features: >-
CASR loss-of-function causes familial hypocalciuric hypercalcemia, a key
differential diagnosis for PHPT-like hypercalcemia because surgery may not
correct the biochemical abnormality.
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Some patients with non-syndromic PHPT may have mutations of the MEN1 gene
or the calcium-sensing receptor (CASR), whose loss of function mutations
usually cause FHH1, a disorder associated with mild hypercalcemia and may
follow a benign clinical course.
explanation: >-
Supports CASR as a PHPT/FHH differential gene relevant to management.
- name: GCM2-associated familial isolated hyperparathyroidism
gene_term:
preferred_term: GCM2
term:
id: hgnc:4198
label: GCM2
association: Predisposing
subtype: Primary MGD
features: >-
GCM2 is included among genes contributing to familial isolated
hyperparathyroidism and hereditary hyperparathyroid presentations.
evidence:
- reference: DOI:10.3390/ijms251910782
reference_title: Heterogeneous Transcriptional Landscapes in Human Sporadic Parathyroid Gland Tumors
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Based on a gene set including MEN1, CDC73, GCM2, CASR, VDR, CCND1, and
CDKN1B, the transcriptomic profiles were analyzed using a cluster analysis.
explanation: >-
Supports inclusion of GCM2 in the molecular landscape considered for
parathyroid tumor biology; it is indirect for familial causality.
- name: RET-associated MEN2A
gene_term:
preferred_term: RET
term:
id: hgnc:9967
label: RET
association: Predisposing
subtype: Primary MGD
features: >-
RET-associated multiple endocrine neoplasia type 2A can include hereditary
primary hyperparathyroidism with multiglandular parathyroid involvement,
although parathyroid disease has lower penetrance than in MEN1.
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The associated syndromic disorders include multiple endocrine neoplasia
types 1–5 (MEN1-5) and hyperparathyroidism with jaw tumor (HPT-JT)
syndromes, and the non-syndromic forms include familial hypocalciuric
hypercalcemia types 1–3 (FHH1-3), familial isolated hyperparathyroidism
(FIHP), and neonatal severe hyperparathyroidism (NS-HPT).
explanation: >-
Supports inclusion of MEN2A within the MEN1-5 hereditary syndromic PHPT
spectrum; RET was verified locally with OAK as hgnc:9967.
- name: CDKN1B-associated MEN4
gene_term:
preferred_term: CDKN1B
term:
id: hgnc:1785
label: CDKN1B
association: Predisposing
subtype: Primary MGD
features: >-
CDKN1B-associated multiple endocrine neoplasia type 4 is a MEN1-like
hereditary PHPT syndrome relevant to multiglandular parathyroid disease and
family screening.
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The associated syndromic disorders include multiple endocrine neoplasia
types 1–5 (MEN1-5) and hyperparathyroidism with jaw tumor (HPT-JT)
syndromes, and the non-syndromic forms include familial hypocalciuric
hypercalcemia types 1–3 (FHH1-3), familial isolated hyperparathyroidism
(FIHP), and neonatal severe hyperparathyroidism (NS-HPT).
explanation: >-
Supports inclusion of MEN4 within the MEN1-5 hereditary syndromic PHPT
spectrum; CDKN1B was verified locally with OAK as hgnc:1785.
diagnosis:
- name: Biochemical Diagnosis
description: >-
Diagnosis is centered on serum calcium and parathyroid hormone patterns, with
PHPT showing hypercalcemia and raised or inappropriately normal PTH, and SHPT
showing persistently elevated PTH with calcium-phosphate disturbance.
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primary hyperparathyroidism (PHPT), a relatively common disorder
characterized by hypercalcemia with raised or inappropriately normal serum
parathyroid hormone (PTH) concentrations, may occur as part of a
hereditary syndromic disorder or as a non-syndromic disease.
explanation: >-
Provides the core biochemical definition for primary hyperparathyroidism.
- name: Localization Imaging
description: >-
Ultrasound, sestamibi/SPECT, CT, MRI, and PET approaches are used for
localization, surgical planning, ectopic tissue assessment, and evaluation of
recurrent disease.
evidence:
- reference: DOI:10.3390/cancers16142593
reference_title: "Imaging Recommendations for Diagnosis and Management of Primary Parathyroid Pathologies: A Comprehensive Review"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Parathyroid pathologies are suspected based on the biochemical alterations
and clinical manifestations, and the predominant roles of imaging in
primary hyperparathyroidism are localisation of tumour within parathyroid
glands, surgical planning, and to look for any ectopic parathyroid tissue
in the setting of recurrent disease.
explanation: >-
Supports localization imaging as a planning and recurrent-disease
assessment tool rather than the primary biochemical diagnostic test.
histopathology:
- name: Multiglandular Parathyroid Disease Pattern
description: >-
Histopathologic and clinicopathologic assessment distinguishes
multiglandular parathyroid disease from solitary adenoma, atypical
parathyroid tumor, and parathyroid carcinoma; in CKD-related disease this
may present as diffuse multiglandular hyperplasia with later refractory
behavior.
evidence:
- reference: DOI:10.3390/cancers16142593
reference_title: "Imaging Recommendations for Diagnosis and Management of Primary Parathyroid Pathologies: A Comprehensive Review"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This article provides a comprehensive review of embryology and anatomical
variations of parathyroid glands and their clinical relevance, surgical
anatomy of parathyroid glands, differentiation between multiglandular
parathyroid disease, solitary adenoma, atypical parathyroid tumour, and
parathyroid carcinoma.
explanation: >-
Supports multiglandular parathyroid disease as a distinct
clinicopathologic pattern relevant to parathyroid hyperplasia.
treatments:
- name: Parathyroidectomy
description: >-
Surgical removal of abnormal parathyroid tissue is the definitive treatment
for surgically eligible PHPT and remains important for refractory secondary
and tertiary hyperparathyroidism.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: DOI:10.3389/fendo.2023.1169793
reference_title: Treatment for secondary hyperparathyroidism focusing on parathyroidectomy
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Treatment for SHPT has changed radically with the advent of calcimimetics;
however, parathyroidectomy (PTx) remains one of the most important
treatments.
explanation: >-
Supports parathyroidectomy as an important therapy for secondary
hyperparathyroidism.
- name: Calcimimetic Pharmacotherapy
description: >-
Calcimimetic therapy, including cinacalcet and etelcalcetide, is used to
reduce parathyroid hormone levels in secondary hyperparathyroidism and can
be combined with other therapies in selected PHPT settings.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: cinacalcet
term:
id: CHEBI:48390
label: cinacalcet
- preferred_term: etelcalcetide
term:
id: CHEBI:134700
label: etelcalcetide
evidence:
- reference: DOI:10.3390/medicina60050812
reference_title: "Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
As a first option for medical treatment, vitamin D receptor analogs
(VDRAs) and calcimimetic agents are generally used.
explanation: >-
Supports calcimimetic pharmacotherapy as a standard medical treatment
category in CKD-related secondary hyperparathyroidism.
- name: Vitamin D Receptor Analog Pharmacotherapy
description: >-
Vitamin D receptor analogs are used as first-option medical therapy for
CKD-related secondary hyperparathyroidism, alongside calcimimetic agents.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: DOI:10.3390/medicina60050812
reference_title: "Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
As a first option for medical treatment, vitamin D receptor analogs
(VDRAs) and calcimimetic agents are generally used.
explanation: >-
Supports vitamin D receptor analogs as first-option medical therapy in
CKD-related secondary hyperparathyroidism.
- name: Denosumab and Cinacalcet Trial Therapy
description: >-
Denosumab with or without cinacalcet has been studied as a medical
alternative for primary hyperparathyroidism patients who do not undergo
surgery.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: cinacalcet
term:
id: CHEBI:48390
label: cinacalcet
- preferred_term: Denosumab
term:
id: NCIT:C61313
label: Denosumab
evidence:
- reference: clinicaltrials:NCT03027557
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
This study aims to evaluate the effects of Denosumab alone, and in
combination with Cinacalcet, as a medical treatment for patients suffering
from primary hyperparathyroidism, with mild osteoporosis.
explanation: >-
Supports investigation of denosumab and cinacalcet as medical therapy for
PHPT when surgery is not performed; trial evidence is not curative evidence
for parathyroid hyperplasia itself.
clinical_trials:
- name: NCT03027557
phase: PHASE_IV
status: COMPLETED
description: >-
DENOCINA trial evaluating denosumab alone and denosumab plus cinacalcet for
primary hyperparathyroidism patients with mild osteoporosis who do not meet
criteria for, or do not wish to undergo, surgery.
target_phenotypes:
- preferred_term: Hypercalcemia
term:
id: HP:0003072
label: Hypercalcemia
- preferred_term: Osteoporosis
term:
id: HP:0000939
label: Osteoporosis
evidence:
- reference: clinicaltrials:NCT03027557
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It is expected that the therapy will be able to both control s-calcium and
s-intact parathyroid hormone (iPTH), and simultaneously enhance
bone-structure.
explanation: >-
Supports the trial's therapeutic targets of calcium, PTH, and skeletal
outcomes.
- name: NCT01421407
phase: PHASE_II
status: WITHDRAWN
description: >-
Trial record for high-intensity focused ultrasound in uncontrolled secondary
hyperparathyroidism in chronic hemodialysis patients with enlarged glands
visible on ultrasound.
target_phenotypes:
- preferred_term: Elevated circulating parathyroid hormone level
term:
id: HP:0003165
label: Elevated circulating parathyroid hormone level
- preferred_term: Parathyroid hyperplasia
term:
id: HP:0008208
label: Parathyroid hyperplasia
evidence:
- reference: clinicaltrials:NCT01421407
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
The aim of this study is to evaluate the efficacy and safety of HIFU
treatment in chronic haemodialysis patients with secondary
hyperparathyroidism presenting with enlarged parathyroid gland(s) which are
visible at ultrasonography and for whom medical therapy has been
unsuccessful.
explanation: >-
Supports the trial's relevance to secondary hyperparathyroidism with
enlarged parathyroid glands; the study record does not establish completed
efficacy results.
differential_diagnoses:
- name: Familial Hypocalciuric Hypercalcemia
description: >-
CASR-related familial hypocalciuric hypercalcemia can mimic PHPT
biochemically and should be distinguished because its course and treatment
implications differ.
evidence:
- reference: DOI:10.1007/s42000-023-00508-9
reference_title: Genetics of hereditary forms of primary hyperparathyroidism
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Measurement of the urinary calcium-to-creatinine ratio clearance (UCCR)
may help to distinguish patients with FHH from those with PHPT, as the
majority of FHH patients have low urinary calcium excretion (UCCR < 0.01).
explanation: >-
Supports FHH as a key differential diagnosis for PHPT-like hypercalcemia.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Parathyroid Hyperplasia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Disease name: Parathyroid hyperplasia (clinical entity spanning PHPT-associated multigland disease; CKD-related secondary hyperplasia; autonomous tertiary disease) (jha2023molecularandclinical pages 8-9, vetter2024whatisthe pages 1-3, costea2025tertiaryhyperparathyroidismin pages 4-6)
Category: Complex (etiologies include sporadic, hereditary, and CKD-driven mineral-bone disorder) (jha2023molecularandclinical pages 8-9, vetter2024whatisthe pages 1-3)
A specific MONDO identifier for the standalone label “parathyroid hyperplasia” was not retrieved in the current full-text corpus. However, MONDO identifiers are available for closely related entities used in practice (e.g., hereditary hyperparathyroidism MONDO_0016166) via Open Targets (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET). This report therefore uses ontology annotations at the phenotype/mechanism/action level (HPO/GO/UBERON/MAXO) plus gene/syndrome identifiers for hereditary forms.
“Parathyroid hyperplasia” refers to enlargement/proliferation of parathyroid tissue and is used in different ways depending on clinical context:
Primary hyperparathyroidism (PHPT) context: multigland involvement historically called “hyperplasia,” now often termed multiglandular parathyroid disease (MGD) in WHO 2022 terminology; clinically defined by >1 abnormal gland rather than a histologic gold standard (jha2023molecularandclinical pages 8-9, chakrabarty2024imagingrecommendationsfor pages 3-5).
Secondary hyperparathyroidism (SHPT) context: CKD-driven compensatory hyperplasia due to chronic disturbances in phosphate/calcitriol/calcium homeostasis (vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2).
Tertiary hyperparathyroidism (tHPT) context:* autonomous hyperparathyroidism after prolonged SHPT (often post-transplant), typically multiglandular (vetter2024whatisthe pages 10-12, costea2025tertiaryhyperparathyroidismin pages 4-6).
Direct abstract-supported statement (PHPT): a 2024 review summarizes causes/relative proportions and states that in PHPT, solitary adenoma is ~80–85% and multiglandular disease is ~10–15% (chakrabarty2024imagingrecommendationsfor pages 1-2).
Not retrievable from the current corpus: ICD-10/ICD-11 codes, MeSH IDs, and Orphanet IDs specifically for “parathyroid hyperplasia.”
PHPT is defined as inappropriate excess PTH relative to calcium due to intrinsic parathyroid pathology; etiologies include single adenoma, MGD (hyperplasia/double adenomas), and carcinoma (jha2023molecularandclinical pages 8-9, chakrabarty2024imagingrecommendationsfor pages 1-2). In PHPT, MGD is enriched in hereditary cases (jha2023molecularandclinical pages 8-9, jha2023molecularandclinical pages 1-2).
Secondary hyperparathyroidism in CKD arises from disturbed mineral metabolism: early CKD features increased FGF-23 with reduced activated vitamin D; progressive CKD yields hyperphosphatemia, reduced activated vitamin D, hypocalcemia, and compensatory parathyroid hyperplasia (hiramitsu2023treatmentforsecondary pages 1-2). A 2024 surgical review explicitly links chronic hypocalcemia, hyperphosphatemia, and low calcitriol to parathyroid hyperplasia (vetter2024whatisthe pages 1-3).
A 2024 review describes the mechanistic progression: prolonged SHPT stimulation can cause nodular remodeling, reduced calcium-sensing/vitamin-D receptor sensitivity, and autonomy; this is the conceptual basis for tertiary HPT, often after kidney transplantation (vetter2024whatisthe pages 1-3). A narrative review defines tertiary HPT as “autonomous parathyroid gland function, hypercalcemia, and progressive enlargement of all four parathyroid glands” (costea2025tertiaryhyperparathyroidismin pages 4-6).
Hereditary forms are clinically important because they are often multiglandular and change operative strategy and family management. Direct abstract-supported statement: “Approximately 15% of patients with PHPT have an underlying heritable form” (jha2023molecularandclinical pages 1-2). A 2024 review states hereditary forms account for >10% of PHPT and provides penetrance estimates for syndromes (english2024geneticsofhereditary pages 1-2).
Key hereditary genes/syndromes include MEN1, CDC73 (HPT-JT), RET (MEN2A), CDKN1B (MEN4), CASR/GNA11/AP2S1 (FHH1–3 differential), and GCM2 (FIHP) (jha2023molecularandclinical pages 15-16, jha2023molecularandclinical pages 23-24, english2024geneticsofhereditary pages 1-2). In one selected high-risk cohort, germline variants were identified in 28.2% (11/39), comprising MEN1 (17.9%) and CDC73 (10.2%) (preprint; interpret cautiously) (qadir2024moleculargeneticsin pages 1-3).
The retrieved corpus does not provide validated “protective factors” (genetic or environmental) that reduce risk of developing parathyroid hyperplasia. However, appropriate CKD-mineral bone disorder management (phosphate control, vitamin D correction) is mechanistically protective against SHPT progression (vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2).
Direct gene–environment interaction studies specific to “parathyroid hyperplasia” were not retrieved in the current corpus. Clinically, gene-driven multigland PHPT (e.g., MEN1) and environment/organ-disease-driven SHPT (CKD) represent distinct but sometimes overlapping pathways to gland enlargement (english2024geneticsofhereditary pages 1-2, vetter2024whatisthe pages 1-3).
Major phenotypes and suggested HPO mappings are summarized in the phenotype table below.
| Phenotype | Suggested HPO term(s) | Frequency / data from sources | Key citations |
|---|---|---|---|
| Hypercalcemia / hypercalcemic crisis | Hypercalcemia [HP:0003072]; Hypercalcemic crisis [HP:0100742] | PHPT is biochemically defined by elevated calcium with unsuppressed/inappropriately normal PTH; in atypical parathyroid adenoma, hypercalcemic crisis occurred in 22.8% overall; subgroup data: 0% and 39.1% in APA, 50.0% and 61.9% in parathyroid carcinoma cohorts (chen2023clinicalandgenetic pages 1-2, chen2023clinicalandgenetic pages 6-8, english2024geneticsofhereditary pages 1-2) | (chen2023clinicalandgenetic pages 1-2, chen2023clinicalandgenetic pages 6-8, english2024geneticsofhereditary pages 1-2) |
| Elevated parathyroid hormone | Increased circulating parathyroid hormone level [HP:0032369] | Severe SHPT (intact PTH >300 pg/mL) occurs in ~33% of CKD-related SHPT cases; in APA median serum PTH was 593.0 pg/mL; recurrence risk after surgery rises when 6-month PTH is ≥80 pg/mL (hiramitsu2023treatmentforsecondary pages 1-2, chen2023clinicalandgenetic pages 1-2, pavlidis2023updateonthe pages 1-2) | (hiramitsu2023treatmentforsecondary pages 1-2, chen2023clinicalandgenetic pages 1-2, pavlidis2023updateonthe pages 1-2) |
| Nephrolithiasis / renal calcification | Nephrolithiasis [HP:0000787]; Nephrocalcinosis [HP:0000129] | Urolithiasis was more frequent in APA than benign lesions (57.0% vs 29.6%); nephrolithiasis/renal calcification occurred in 87.5% and 43.5% of APA subgroups and 88.2% and 71.4% of carcinoma subgroups; PHPT is broadly associated with kidney stones and CKD (chen2023clinicalandgenetic pages 1-2, chen2023clinicalandgenetic pages 6-8, jha2023molecularandclinical pages 1-2) | (chen2023clinicalandgenetic pages 1-2, chen2023clinicalandgenetic pages 6-8, jha2023molecularandclinical pages 1-2) |
| Chronic kidney disease / renal failure | Chronic kidney disease [HP:0012622]; Renal insufficiency [HP:0000083] | CKD is a recognized morbidity of PHPT; in parathyroid carcinoma literature renal involvement including stones and renal failure occurred in 37.2% (347/932) across 27 studies; CKD also drives secondary hyperplasia/SHPT (jha2023molecularandclinical pages 7-8, roser2023diagnosisandmanagement pages 3-5, vetter2024whatisthe pages 1-3) | (jha2023molecularandclinical pages 7-8, roser2023diagnosisandmanagement pages 3-5, vetter2024whatisthe pages 1-3) |
| Bone involvement / renal osteodystrophy | Abnormality of the skeleton [HP:0000924]; Renal osteodystrophy [HP:0003338] | Bone involvement in APA was 35.4% vs 62.0% in parathyroid carcinoma; subgroup data showed bone involvement in 33.3% and 39.1% of APA and 58.8% and 71.4% of carcinoma cases; SHPT causes osteodystrophy and fractures (chen2023clinicalandgenetic pages 1-2, chen2023clinicalandgenetic pages 6-8, hiramitsu2023treatmentforsecondary pages 1-2) | (chen2023clinicalandgenetic pages 1-2, chen2023clinicalandgenetic pages 6-8, hiramitsu2023treatmentforsecondary pages 1-2) |
| Fragility fractures / fractures | Pathologic fracture [HP:0002659]; Increased susceptibility to fractures [HP:0002757] | Fragility fractures were reported in 33.3% and 17.4% of APA subgroups and 31.3% and 28.6% of carcinoma subgroups; PHPT is associated with fractures, and parathyroidectomy reduced overall fracture risk by 15% in a later meta-analysis summarized in retrieved literature (primary source data here from 2023 cohorts/reviews) (chen2023clinicalandgenetic pages 6-8, jha2023molecularandclinical pages 1-2) | (chen2023clinicalandgenetic pages 6-8, jha2023molecularandclinical pages 1-2) |
| Osteoporosis / cortical bone loss / osteopenia | Osteoporosis [HP:0000939]; Osteopenia [HP:0000938]; Decreased bone mineral density [HP:0004349] | Bone involvement in hyperparathyroid disease commonly includes osteoporosis/osteopenia; carcinoma review reported bone manifestations in 45.8% overall and noted preferential cortical loss (e.g., distal one-third radius BMD reduction) (roser2023diagnosisandmanagement pages 3-5, roser2023diagnosisandmanagement pages 7-8) | (roser2023diagnosisandmanagement pages 3-5, roser2023diagnosisandmanagement pages 7-8) |
| Bone and muscle pain / weakness | Bone pain [HP:0002653]; Muscular hypotonia [HP:0001252] / Muscle weakness [HP:0001324] | In parathyroid carcinoma review, bone plus muscle pain/weakness formed part of the 45.8% overall bone-manifestation category; these symptoms are also highlighted among common presentations of hyperparathyroid disease (roser2023diagnosisandmanagement pages 3-5) | (roser2023diagnosisandmanagement pages 3-5) |
| Gastrointestinal symptoms | Abdominal pain [HP:0002027]; Nausea [HP:0002018]; Vomiting [HP:0002013] | Gastrointestinal symptoms occurred in 17.7% of APA vs 41.8% of parathyroid carcinoma; GI complications were also more common in tertiary HPT hemodialysis cohorts in later literature (chen2023clinicalandgenetic pages 1-2) | (chen2023clinicalandgenetic pages 1-2) |
| Neuropsychiatric symptoms / fatigue | Neuropsychiatric abnormality [HP:0011446]; Fatigue [HP:0012378] | In carcinoma literature, fatigue occurred in 13.6% (127 patients), and neuropsychiatric symptoms were also commonly reported; PHPT can present with nonspecific symptoms that delay diagnosis (roser2023diagnosisandmanagement pages 3-5, jha2023molecularandclinical pages 1-2) | (roser2023diagnosisandmanagement pages 3-5, jha2023molecularandclinical pages 1-2) |
| Multiglandular disease / four-gland hyperplasia | Multiple endocrine gland hyperplasia [HP:0006779] | Multigland disease accounts for about 10–15% of PHPT; in tertiary HPT, ~90% had multiglandular disease, with only 10% single-gland disease and 30% two-gland involvement reported in one 2024 review (chakrabarty2024imagingrecommendationsfor pages 1-2, pavlidis2023updateonthe pages 1-2, vetter2024whatisthe pages 10-12) | (chakrabarty2024imagingrecommendationsfor pages 1-2, pavlidis2023updateonthe pages 1-2, vetter2024whatisthe pages 10-12) |
| Hypocalciuria in familial hypocalciuric hypercalcemia differential | Hypocalciuria [HP:0012023] | Important differential phenotype rather than direct complication: most FHH patients have UCCR <0.01; about 80–95% of FHH cases show calcium/creatinine clearance ratio <0.01, helping distinguish FHH from PHPT/hyperplasia (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 23-24) | (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 23-24) |
Table: This table maps major clinical and laboratory phenotypes relevant to parathyroid hyperplasia and hyperparathyroidism to suggested HPO terms, with recent quantitative data where available. It is useful for structuring phenotype annotations in a disease knowledge base.
A 2023 SHPT surgical review states parathyroidectomy is associated with improved quality of life (alongside improved bone density, fracture risk, and survival) (hiramitsu2023treatmentforsecondary pages 1-2). Quantitative QoL instrument scores (e.g., SF-36/EQ-5D) were not present in the retrieved corpus.
Key hereditary genes are summarized here and in the genetics table:
| Gene | Syndrome / phenotype | Inheritance | Typical parathyroid pattern | Key statistics / notes | Key citations |
|---|---|---|---|---|---|
| MEN1 | Multiple endocrine neoplasia type 1 (syndromic hereditary PHPT) | Autosomal dominant | Typically multifocal/multiglandular disease; often described clinically as hyperplasia/MGD rather than single adenoma | Most common syndromic cause of hereditary PHPT; hereditary PHPT accounts for ~10% to >10% of PHPT overall; MEN1 penetrance for PHPT reported ~90% by age 70; somatic MEN1 alterations also occur in sporadic tumors (~12–35% in reviews) (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 3-4) | PMID 36778668 cited via Open Targets; review DOI: 10.1210/endrev/bnad009 (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 3-4) |
| CDC73 | Hyperparathyroidism-jaw tumor syndrome (HPT-JT); also familial isolated PHPT and parathyroid carcinoma predisposition | Autosomal dominant | Can present with multigland disease, but especially important for carcinoma-risk PHPT; not limited to diffuse hyperplasia | HPT-JT has incomplete penetrance; reported parathyroid carcinoma risk ~20–25%; in a selected high-risk Indian cohort, 4/39 (10.2%) had CDC73 variants; germline CDC73 was the commonest abnormality in atypical parathyroid adenoma and carcinoma cohorts in one study (qadir2024moleculargeneticsin pages 1-3, jha2023molecularandclinical pages 15-16, simonds2020clinicalandmolecular pages 4-6) | Review DOI: 10.1210/endrev/bnad009; cohort DOI: 10.21203/rs.3.rs-5299691/v1 (qadir2024moleculargeneticsin pages 1-3, jha2023molecularandclinical pages 15-16, simonds2020clinicalandmolecular pages 4-6) |
| RET | Multiple endocrine neoplasia type 2A (MEN2A) | Autosomal dominant | Usually not the dominant parathyroid presentation; may cause parathyroid tumors/hyperplasia, often with medullary thyroid carcinoma and pheochromocytoma | Lower penetrance than MEN1; English et al. report MEN2 PHPT ~5–15%; large MEN2A cohort (1085 patients) had only 10 patients initially presenting with PHPT, suggesting low yield of RET testing in isolated PHPT (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 15-16) | Review DOI: 10.1007/s42000-023-00508-9; review DOI: 10.1210/endrev/bnad009 (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 15-16) |
| CDKN1B | MEN4 (MEN1-like syndrome) | Autosomal dominant | Often multiglandular / MEN1-like hereditary PHPT rather than isolated single-gland disease | MEN4 is rarer than MEN1; penetrance for PHPT reported ~75% in review summaries; included on hereditary PHPT testing panels because results affect surgical planning and family testing (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 4-6) | Review DOI: 10.1007/s42000-023-00508-9; ClinVar/Open Targets evidence noted for CDKN1B (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 4-6) |
| CASR | Familial hypocalciuric hypercalcemia type 1 (FHH1); related neonatal severe hyperparathyroidism when biallelic severe loss-of-function | Autosomal dominant for FHH1; biallelic severe forms for NSHPT | Usually not classic hyperplastic PHPT; causes lifelong mild hypercalcemia with inappropriately normal/high PTH and can mimic PHPT; important differential diagnosis to avoid unnecessary PTX | FHH prevalence ~1.3 per 100,000 and accounts for about 2% of apparent PHPT; UCCR <0.01 typical in ~80–95% of FHH; CASR is among the most frequently positive genes in hereditary PHPT testing cohorts (11/19 positives in one UK series were CASR) (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 23-24) | PMIDs in Open Targets include 15572418, 27434672; review DOI: 10.1007/s42000-023-00508-9 (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 23-24) |
| GNA11 | Familial hypocalciuric hypercalcemia type 2 (FHH2) | Autosomal dominant | Usually FHH phenotype rather than true multigland hyperplasia | Included in hereditary hypercalcemia/PHPT differential; like CASR-related FHH, tends to show hypocalciuria and generally benign course rather than surgically correctable hyperplasia (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 15-16, jha2023molecularandclinical pages 23-24) | Review DOI: 10.1210/endrev/bnad009; review DOI: 10.1007/s42000-023-00508-9 (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 15-16, jha2023molecularandclinical pages 23-24) |
| AP2S1 | Familial hypocalciuric hypercalcemia type 3 (FHH3) | Autosomal dominant | Usually FHH mimic, not classic multigland hyperplasia | Nearly all pathogenic variants affect Arg15 in reported series; in a UK hereditary PHPT testing cohort, 1/19 pathogenic findings was AP2S1; clinically relevant because parathyroidectomy usually does not correct FHH (english2024geneticsofhereditary pages 8-9, jha2023molecularandclinical pages 23-24) | Review DOI: 10.1007/s42000-023-00508-9; review DOI: 10.1210/endrev/bnad009 (english2024geneticsofhereditary pages 8-9, jha2023molecularandclinical pages 23-24) |
| GCM2 | Familial isolated hyperparathyroidism (FIHP); activating variants also linked to hereditary PHPT | Usually autosomal dominant with variable/low penetrance | Can be associated with multigland disease / familial hyperplasia-like PHPT, but penetrance is variable and many families remain unexplained | Activating GCM2 variants reported in ~18% of FIHP in some series; among FIHP kindreds pre-screened negative for MEN1/CASR/CDC73, only ~10–20% carry GCM2 variants, leaving ~80–90% unexplained; low penetrance has raised questions about routine panel inclusion in all settings (jha2023molecularandclinical pages 23-24, qadir2024moleculargeneticsin pages 9-11) | PMIDs in Open Targets include 27745835, 39024449, 36653562 (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, jha2023molecularandclinical pages 23-24, qadir2024moleculargeneticsin pages 9-11) |
Table: This table summarizes the main hereditary genes linked to parathyroid hyperplasia, multiglandular disease, or closely related hereditary PHPT phenotypes. It highlights inheritance, the usual parathyroid pattern, and key statistics that help distinguish true multigland disease from mimics such as familial hypocalciuric hypercalcemia.
Notable gene-level points (selected):
* MEN1 is the most common syndromic cause of hereditary PHPT; sporadic tumors also frequently show somatic MEN1 alterations (review summaries) (english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 3-4).
CDC73 (HPT-JT) confers clinically important carcinoma risk (reported ~20–25% in a 2023 review summary) and needs long-term surveillance approaches in carriers (jha2023molecularandclinical pages 15-16, simonds2020clinicalandmolecular pages 4-6).
CASR/GNA11/AP2S1 mutations cause familial hypocalciuric hypercalcemia (FHH), which mimics PHPT but is usually not corrected by parathyroidectomy (jha2023molecularandclinical pages 15-16, jha2023molecularandclinical pages 23-24).
The retrieved corpus did not provide a comprehensive ClinVar-style variant catalog for parathyroid hyperplasia. However, one 2024 cohort report lists multiple MEN1 and CDC73 variants detected by NGS panel in a selected high-risk set (qadir2024moleculargeneticsin pages 1-3). For knowledge base entry, variant-level data should be completed by targeted ClinVar/HGMD extraction.
A 2023 Endocrine Reviews synthesis notes that reduced CASR expression is common in sporadic PHPT tumors and may be driven by epigenetic deregulation (hypermethylation and histone modifications) and altered upstream regulators (jha2023molecularandclinical pages 11-12). The same review highlights broad epigenetic alterations and noncoding RNA regulation as potentially reversible contributors (jha2023molecularandclinical pages 11-12).
A 2024 study profiled 32 sporadic parathyroid adenomas with gene, microRNA, and lncRNA expression, clustering tumors by a MEN1/CDC73/GCM2/CASR/VDR/CCND1/CDKN1B gene set; CDC73 and CDKN1B expression drove clustering, and distinct lncRNA patterns were associated with biochemical severity differences (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2, verdelli2024heterogeneoustranscriptionallandscapes pages 7-9). This provides a current example of molecular heterogeneity relevant to understanding why some tumors behave more “quiescent” vs “severe” clinically (verdelli2024heterogeneoustranscriptionallandscapes pages 7-9).
The dominant “environmental” drivers in the retrieved corpus are organ-disease mediated exposures, especially CKD-related mineral and endocrine disturbance:
* CKD-related drivers: hyperphosphatemia, calcitriol deficiency, hypocalcemia, elevated FGF23, and related inflammatory/oxidative mechanisms contribute to hyperplasia and SHPT progression (hiramitsu2023treatmentforsecondary pages 1-2, costea2025tertiaryhyperparathyroidismin pages 2-4).
* No infectious triggers were identified in the retrieved corpus.
PHPT MGD reflects intrinsic multi-gland pathology (often genetic susceptibility-driven) and is described clinically by multiple abnormal glands; WHO 2022 favors MGD terminology and notes limited histologic discriminability between adenoma vs hyperplasia in practice (jha2023molecularandclinical pages 8-9, chakrabarty2024imagingrecommendationsfor pages 3-5).
A 2023 Endocrine Reviews article provides sex-stratified incidence estimates for PHPT: ~66 per 100,000 person-years in women and ~25 per 100,000 in men (jha2023molecularandclinical pages 7-8). It also reports that PHPT is associated with fractures, kidney stones, CKD, and increased mortality (jha2023molecularandclinical pages 7-8).
| Workup component | What to measure/use | Key findings or performance statistics | Notes specific to multigland disease / secondary HPT | Key citations |
|---|---|---|---|---|
| Biochemical diagnosis | Serum total calcium, ionized calcium, intact PTH | PHPT is diagnosed by hypercalcemia with elevated or inappropriately normal PTH; one cohort used serum Ca >2.70 mmol/L and/or ionized Ca >1.28 mmol/L with unsuppressed PTH as diagnostic thresholds | Biochemistry alone cannot reliably distinguish adenoma from hyperplasia/MGD; markedly high calcium and PTH may raise concern for carcinoma rather than benign MGD | (chakrabarty2024imagingrecommendationsfor pages 1-2, chen2023clinicalandgenetic pages 1-2, english2024geneticsofhereditary pages 1-2) |
| Mineral metabolism panel | Serum phosphate, 25-OH vitamin D, renal function | In CKD-related SHPT, progressive hyperphosphatemia and reduced active vitamin D drive hypocalcemia and compensatory parathyroid hyperplasia; vitamin D status is important for surgical outcomes and recurrence risk | Particularly important in SHPT/tHPT to separate CKD-mineral bone disorder from primary disease and to optimize pre-/post-operative management | (pavlidis2023updateonthe pages 1-2, vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2) |
| Urinary calcium assessment | Urinary calcium-to-creatinine clearance ratio (UCCR/UCCR) | Majority of FHH patients have UCCR <0.01; FHH accounts for about 2% of patients initially considered to have PHPT in some series | Essential when apparent PHPT presents with mild hypercalcemia or familial disease; helps avoid unnecessary parathyroidectomy in FHH | (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 23-24) |
| Neck ultrasound | First-line anatomic localization | Widely used first-line tool; pooled sensitivity for US in prior meta-analysis about 80% for PHPT localization | Lower sensitivity in MGD and renal hyperplasia; in renal HPT/hyperplastic glands, sonography sensitivity reported around 62% | (scheepers2023diagnosticperformanceof pages 13-14, vetter2024whatisthe pages 10-12, chakrabarty2024imagingrecommendationsfor media a62b0df1) |
| Sestamibi scintigraphy / SPECT/CT | Functional localization with 99mTc-sestamibi, often with SPECT/CT | Prior meta-analysis pooled sensitivity about 83% for MIBI in PHPT localization | Performance drops in MGD: reported MIBI sensitivity about 44% for MGD; in renal HPT/hyperplastic glands scintigraphy sensitivity around 55% | (scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 14-15, vetter2024whatisthe pages 10-12) |
| 4DCT | Multiphasic CT for localization and MGD prediction | One meta-analysis cited sensitivity 81.0% for 4DCT vs 65.0% for MIBI; MGD sensitivity reported about 60%; 4DCT MGD prediction scores: composite score specificity 72% (>=4), 86% (>=5), 100% (=6), CT-only score specificity 74% (>=3) and 88% (>=4) | Helpful when first-line imaging is negative or recurrent disease is suspected; exposes patients to ionizing radiation; useful for predicting MGD before surgery | (chakrabarty2024imagingrecommendationsfor pages 9-11, scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 14-15) |
| MRI / 4D MRI | Radiation-free localization, dynamic contrast-enhanced protocols | Conventional MRI sensitivity 39.1%-94.3%; 4D MRI sensitivity 55.6%-100%; first-line 4D MRI often 64%-100%; reported MGD sensitivity 67%-100%; one review cited 92% for single-gland disease and 74% for MGD | Attractive in younger patients, recurrent disease, and when radiation avoidance matters; superior to conventional imaging in some reoperative/MGD settings | (chakrabarty2024imagingrecommendationsfor pages 9-11, scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 9-11, scheepers2023diagnosticperformanceof pages 1-2) |
| 18F-FCH PET/CT | High-resolution functional imaging | Reported as superior to ultrasound and MIBI; accepted as an alternative first-line modality in some centers | Useful in difficult localization, persistent/recurrent disease, and MGD; increasingly used before reoperation | (chakrabarty2024imagingrecommendationsfor pages 9-11, pavlidis2023updateonthe pages 1-2, scheepers2023diagnosticperformanceof pages 2-4, chakrabarty2024imagingrecommendationsfor media a62b0df1) |
| PET/MRI | Hybrid metabolic + high-contrast soft tissue imaging | 18F-FCH PET/MRI sensitivity 84.2%-100%; specificity 96.0%-100% in reported studies; described as highest diagnostic accuracy among MRI-based approaches | Particularly useful for MGD, pediatric patients, and complex surgical planning while minimizing radiation | (scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 9-11, chakrabarty2024imagingrecommendationsfor pages 9-11) |
| Intraoperative PTH monitoring | Rapid ioPTH during parathyroidectomy | In PHPT/reoperative disease, PTH <=40 pg/mL or >=50% drop from baseline minimizes persistence risk; Miami criterion (>50% drop at >=10 min) is used in tertiary/renal HPT surgery literature | In SHPT, formal ioPTH criteria are less established because all hyperplastic glands must be removed; nevertheless, intraoperative monitoring may support completeness of resection | (pavlidis2023updateonthe pages 1-2, costea2025tertiaryhyperparathyroidismin pages 10-12, hiramitsu2023treatmentforsecondary pages 1-2) |
| Postoperative surveillance | Serum calcium and PTH follow-up | Six-month calcium >=9.8 mg/dL and PTH >=80 pg/mL indicate higher recurrence risk after PHPT surgery | Four-gland hyperplasia/double adenomas have higher persistence/recurrence risk, so long-term follow-up is especially important | (pavlidis2023updateonthe pages 1-2) |
| Strategy for MGD / renal hyperplasia | Bilateral neck exploration, selective imaging, four-gland assessment | Figure-based management algorithms recommend imaging for planning, then bilateral neck exploration with subtotal or total parathyroidectomy for MGD; in tHPT, 90% have multiglandular disease | In SHPT/tHPT, localization imaging is adjunctive; operative four-gland exploration remains the most reliable strategy because hyperplasia is often diffuse/multiglandular | (vetter2024whatisthe pages 10-12, vetter2024whatisthe pages 1-3, chakrabarty2024imagingrecommendationsfor media 9629bfff) |
Table: This table summarizes the current diagnostic workup for parathyroid hyperplasia and related hyperparathyroid states, including key laboratory tests, localization imaging, intraoperative monitoring, and special considerations for multigland disease and CKD-related secondary/tertiary hyperparathyroidism.
Key recent imaging developments relevant to “hyperplasia” (MGD):
MRI systematic review (Dec 2023): conventional MRI sensitivity 39.1–94.3%; 4D MRI 55.6–100%; PET/MRI (18F-FCH) 84.2–100% (scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 9-11). In MGD specifically, reported MRI sensitivities 67–100%, versus MIBI ~44% and 4DCT ~60% in cited comparisons (scheepers2023diagnosticperformanceof pages 14-15).
2024 imaging review: provides a dedicated management branch for MGD (formerly hyperplasia) recommending imaging for planning and then bilateral neck exploration with subtotal/total parathyroidectomy (algorithm figure) (chakrabarty2024imagingrecommendationsfor media a62b0df1). The same source includes a summary table of imaging modalities (advantages/limitations) (chakrabarty2024imagingrecommendationsfor media 9629bfff).
A 2024 genetics review recommends urinary calcium-to-creatinine clearance ratio (UCCR) testing; most FHH cases have UCCR < 0.01, supporting distinction from PHPT/MGD and preventing unnecessary surgery (english2024geneticsofhereditary pages 1-2).
Genetic testing is recommended for individuals with multigland disease, recurrent PHPT, young onset, or family history (jha2023molecularandclinical pages 1-2). A 2024 genetics review similarly recommends testing when hereditary PHPT is suspected (e.g., young age, multigland/hyperplasia, carcinoma, known familial mutation) because results guide surgery and surveillance (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2).
A 2023 surgical-management review reports recurrence after parathyroidectomy historically 4–10%, decreasing to 2.5–5% with modern advances; hyperplasia/MGD is a risk factor for persistence/recurrence (pavlidis2023updateonthe pages 1-2). It provides pragmatic thresholds: intraoperative PTH ≤40 pg/mL or ≥50% drop predicts low persistence risk; and at 6 months, calcium ≥9.8 mg/dL and PTH ≥80 pg/mL indicate recurrence risk (pavlidis2023updateonthe pages 1-2).
A 2024 transplant-focused surgical review reports that (in cited retrospective comparisons) parathyroidectomy produced higher PTH normalization and lower kidney allograft loss versus cinacalcet (9% vs 33% graft failure) (vetter2024whatisthe pages 10-12).
| Context | Treatment / implementation | Real-world use / indication | Key outcomes or statistics | Trial / source |
|---|---|---|---|---|
| PHPT with multigland disease (formerly “hyperplasia”; WHO 2022 favors MGD terminology) | Bilateral neck exploration (BNE) with subtotal or total parathyroidectomy | Preferred operative pathway when multigland disease is suspected/localized poorly; imaging mainly supports planning, but definitive management is surgical exploration | Figure-based algorithm recommends imaging ± parathyroid venous sampling, then BNE followed by subtotal/total parathyroidectomy for MGD; multigland disease/hyperplasia is associated with higher persistence/recurrence risk after surgery than single-gland disease (chakrabarty2024imagingrecommendationsfor media a62b0df1, pavlidis2023updateonthe pages 1-2) | Chakrabarty 2024; Pavlidis 2023 (chakrabarty2024imagingrecommendationsfor media a62b0df1, pavlidis2023updateonthe pages 1-2) |
| PHPT, persistent/recurrent disease risk management | Intraoperative PTH monitoring during parathyroidectomy | Used to reduce risk of persistence in resection for pHPT, including cases with multigland disease | Intraoperative PTH ≤ 40 pg/mL or a ≥50% drop from baseline minimized persistence risk; recurrence risk higher with double adenomas/four-gland hyperplasia; modern recurrence rates reported ~2.5–5% (pavlidis2023updateonthe pages 1-2) | Pavlidis 2023 (pavlidis2023updateonthe pages 1-2) |
| PHPT managed medically when surgery is not performed or delayed | Cinacalcet, denosumab, or combination (plus vitamin D) | Investigated for biochemical control and bone protection in primary hyperparathyroidism; not curative for multigland disease but relevant where surgery is deferred/inappropriate | DENOCINA phase 3 trial enrolled 46 patients; combined arm used denosumab 60 mg every 6 months + cinacalcet 30 mg daily + vitamin D 50 μg daily; endpoints included DXA BMD, serum calcium, PTH, bone turnover markers, nephrolithiasis/nephrocalcinosis imaging outcomes (NCT03027557 chunk 1, NCT03027557 chunk 2, NCT03027557 chunk 3) | NCT03027557 / DENOCINA (NCT03027557 chunk 1, NCT03027557 chunk 2, NCT03027557 chunk 3) |
| CKD-related secondary hyperparathyroidism (SHPT) | Phosphate control: dietary phosphate restriction and phosphate binders | First-line background management to reduce chronic parathyroid stimulation in CKD-mineral bone disorder | Standard therapy in SHPT; used alongside vitamin D analogs and calcimimetics before considering surgery (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3, NCT01421407 chunk 1) | Vetter 2024; Sevva 2024; NCT01421407 background (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3, NCT01421407 chunk 1) |
| CKD-related SHPT | Vitamin D receptor activators/analogs (calcitriol, alfacalcidol/alphacalcidol, doxercalciferol, paricalcitol; others in regional practice) | Common medical therapy for hypocalcemia-driven PTH excess | Recommended pharmacologic option in CKD SHPT; used with phosphate lowering and/or calcimimetics; tertiary HPT review notes they lower PTH, though vascular calcification effects remain debated (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3, costea2025tertiaryhyperparathyroidismin pages 9-10) | Vetter 2024; Sevva 2024; Costea 2025 (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3, costea2025tertiaryhyperparathyroidismin pages 9-10) |
| CKD-related SHPT | Calcimimetics: cinacalcet (oral) | Widely used for refractory biochemical SHPT on dialysis | Background/eligibility in HIFU trial required PTH >800 pg/mL despite ≥3 months cinacalcet >30 mg/day ± vitamin D; cinacalcet also reported to improve endothelial dysfunction/cardiac hypertrophy in hemodialysis patients in reviewed literature (NCT01421407 chunk 1, vetter2024whatisthe pages 17-18) | NCT01421407; Vetter 2024 (NCT01421407 chunk 1, vetter2024whatisthe pages 17-18) |
| CKD-related SHPT | Calcimimetics: etelcalcetide (IV during dialysis) | Real-world dialysis implementation as second-generation calcimimetic | In a 2018–2023 retrospective cohort of 52 dialysis patients, 34/52 (65.4%) received cinacalcet and etelcalcetide; 29/33 (87.9%) treated with etelcalcetide had significant PTH reduction, up to 57% from baseline; none required parathyroidectomy for refractory PTH or drug toxicity in that series (sevva2024pharmaceuticalmanagementof pages 1-2) | Sevva 2024 (sevva2024pharmaceuticalmanagementof pages 1-2) |
| CKD-related SHPT, drug-refractory disease | Parathyroidectomy (subtotal PTX, total PTX with autotransplantation, or total PTX without autotransplantation; sometimes with transcervical thymectomy) | Reserved for refractory SHPT, severe symptoms, or failure/cost issues of medical therapy | Review emphasizes PTx remains one of the most important therapies despite calcimimetics; complete removal of all glands is crucial to prevent persistence/recurrence; PTx associated with improved bone density, fracture risk, survival, and quality of life (hiramitsu2023treatmentforsecondary pages 1-2) | Hiramitsu 2023 (hiramitsu2023treatmentforsecondary pages 1-2) |
| CKD-related SHPT in transplant candidates | Subtotal PTX or total PTX with autotransplantation | Preferred when future kidney transplantation is anticipated | 2024 surgical review recommends subtotal PTX or total PTX with autotransplantation for transplant-eligible patients; total PTX can be considered for non-transplant candidates (vetter2024whatisthe pages 1-3) | Vetter 2024 (vetter2024whatisthe pages 1-3) |
| Post-transplant tertiary hyperparathyroidism (tHPT) | Subtotal parathyroidectomy with four-gland exploration | Favored surgical approach for persistent autonomous post-transplant disease, usually multiglandular | Review states 90% of tHPT patients have multigland disease; subtotal PTX is favored because it has lower hypoparathyroidism risk than total PTX with autotransplantation with similar cure rates (vetter2024whatisthe pages 10-12) | Vetter 2024 (vetter2024whatisthe pages 10-12) |
| Post-transplant tertiary hyperparathyroidism (tHPT) | Timing of parathyroidectomy before vs after transplant | Individualized based on suspected autonomy, graft considerations, and biochemical persistence | If autonomy is suspected, surgery ideally precedes transplantation; if post-transplant surgery is needed, many centers delay until ~1 year; persistent sHPT/tHPT reported to decline from 70% at 1 year to 43% at 2 years post-transplant (vetter2024whatisthe pages 1-3); a meta-analysis of 223 patients found no significant difference between pre- vs post-transplant PTX for follow-up PTH or calcium (vetter2024whatisthe pages 1-3) | Vetter 2024; Karniadakis 2025 abstracted in search results (vetter2024whatisthe pages 1-3) |
| Post-transplant tertiary hyperparathyroidism (tHPT) | Surgery vs cinacalcet | Comparative management for persistent autonomous disease after transplant | Retrospective comparison cited in 2024 review found parathyroidectomy achieved higher PTH normalization and lower graft failure than cinacalcet (9% vs 33% allograft loss) (vetter2024whatisthe pages 10-12) | Vetter 2024 (vetter2024whatisthe pages 10-12) |
| Procedural/ablative alternative for SHPT | High-intensity focused ultrasound (HIFU; TH-One device) | Investigational non-surgical ablation for uncontrolled SHPT in chronic hemodialysis with 1–2 enlarged glands on ultrasound | Randomized open-label trial planned primary endpoint of ≥30% reduction in mean serum iPTH at 6 months and secondary endpoint of achieving KDIGO-range PTH; required uncontrolled disease despite cinacalcet; study was withdrawn with actual enrollment = 0 (NCT01421407 chunk 1) | NCT01421407 (NCT01421407 chunk 1) |
Table: This table summarizes treatment strategies and real-world implementation of therapies for parathyroid hyperplasia across primary multigland disease, CKD-related secondary hyperparathyroidism, and post-transplant tertiary hyperparathyroidism. It highlights surgical standards, medical therapies, response statistics, and relevant clinical trial identifiers.
A 2024 review emphasizes multigland disease (~90%) and generally favors subtotal parathyroidectomy with four-gland exploration (vetter2024whatisthe pages 10-12).
No naturally occurring non-human species datasets for “parathyroid hyperplasia” were retrieved in the current corpus.
Direct primary model-organism papers were not retrieved as full text in the current corpus; however, authoritative reviews cite several mechanistic models relevant to hyperplasia/tumorigenesis:
* Parathyroid-specific Casr loss → severe hyperparathyroidism (jha2023molecularandclinical pages 11-12).
MEN1 loss → parathyroid hyperplasia/adenomas (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).
CDC73 deletion → tumor formation (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).
CDKN1B (p27)* loss → adenoma predisposition (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).
The following tables consolidate the most actionable structured content.
| Classification / concept | Concise definition | Typical biochemical pattern | Typical gland involvement | Terminology / key notes | Key citations |
|---|---|---|---|---|---|
| Primary parathyroid hyperplasia in PHPT / multigland disease (MGD) | In primary hyperparathyroidism, excess PTH arises from intrinsic parathyroid disease; multigland disease includes diffuse four-gland hyperplasia and double adenomas, rather than a single adenoma. | Usually hypercalcemia with inappropriately normal or elevated PTH; phosphate often low-normal/low in PHPT. | More than one gland affected; commonly 4-gland hyperplasia or double adenomas. | WHO 2022 favors “multiglandular parathyroid disease (MGD)” over “hyperplasia” in the PHPT setting; histology alone does not reliably distinguish hyperplasia from adenoma, so distinction is largely clinical (single- vs multigland disease). | (jha2023molecularandclinical pages 8-9, chakrabarty2024imagingrecommendationsfor pages 1-2, pavlidis2023updateonthe pages 1-2, chakrabarty2024imagingrecommendationsfor pages 3-5, english2024geneticsofhereditary pages 1-2) |
| Sporadic PHPT with MGD frequency context | Sporadic PHPT is usually single-gland, but a minority present with MGD/hyperplasia. | Hypercalcemia with elevated or unsuppressed PTH. | Solitary adenoma ~80–85%; MGD/hyperplasia ~10–15%; double adenoma ~4–5%. | Hyperplasia/MGD is clinically important because it raises risk of persistence/recurrence after surgery. | (chakrabarty2024imagingrecommendationsfor pages 1-2, pavlidis2023updateonthe pages 1-2) |
| Secondary parathyroid hyperplasia (CKD-related SHPT) | CKD-associated disturbances in phosphate, calcitriol, calcium, and FGF23-Klotho signaling chronically stimulate the glands, causing compensatory hyperplasia that may progress to nodular hyperplasia. | PTH elevated; calcium typically low or normal; phosphate often elevated in advanced CKD; calcitriol reduced. | Usually diffuse multigland involvement of all 4 glands; nodular remodeling may emerge over time. | Recent reviews note that the term “hyperplasia” is generally reserved for secondary hyperplasia in CKD. Severe SHPT (iPTH >300 pg/mL) was reported in ~33% in one 2023 review. | (jha2023molecularandclinical pages 7-8, vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2, sevva2024pharmaceuticalmanagementof pages 1-2) |
| Tertiary parathyroid hyperplasia / tertiary hyperparathyroidism (tHPT) | Autonomous hyperparathyroidism that develops after prolonged SHPT, classically after kidney transplantation or longstanding CKD, when glands lose normal calcium/vitamin D responsiveness. | Persistently elevated PTH with hypercalcemia; phosphate variable, often less overtly elevated than in SHPT and may normalize after transplant. | Predominantly multigland disease; progressive enlargement of all 4 glands is typical. | One 2024 review reported ~90% of tHPT patients have multigland disease; persistent post-transplant disease remains common, declining from ~70% at 1 year to ~43% at 2 years in cited series. | (vetter2024whatisthe pages 10-12, vetter2024whatisthe pages 1-3, costea2025tertiaryhyperparathyroidismin pages 4-6, costea2025tertiaryhyperparathyroidismin pages 2-4) |
| Transition from SHPT to tHPT | Chronic polyclonal stimulation in SHPT can evolve to nodular/partly monoclonal growth with reduced CaSR/VDR sensitivity, producing autonomy and medical refractoriness. | SHPT: high PTH with low/normal Ca; tHPT: high PTH with high Ca. | Starts as diffuse CKD-related multigland hyperplasia and can progress to autonomous multigland disease. | This mechanistic transition explains why refractory renal hyperparathyroidism often requires subtotal or total parathyroidectomy rather than medical therapy alone. | (vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2, costea2025tertiaryhyperparathyroidismin pages 4-6) |
Table: This table summarizes the main clinical classifications of parathyroid hyperplasia and related multigland disease, contrasting primary PHPT-associated MGD with CKD-related secondary hyperplasia and autonomous tertiary disease. It also highlights the WHO 2022 terminology shift toward 'multiglandular parathyroid disease' in PHPT.
| Gene | Syndrome / phenotype | Inheritance | Typical parathyroid pattern | Key statistics / notes | Key citations |
|---|---|---|---|---|---|
| MEN1 | Multiple endocrine neoplasia type 1 (syndromic hereditary PHPT) | Autosomal dominant | Typically multifocal/multiglandular disease; often described clinically as hyperplasia/MGD rather than single adenoma | Most common syndromic cause of hereditary PHPT; hereditary PHPT accounts for ~10% to >10% of PHPT overall; MEN1 penetrance for PHPT reported ~90% by age 70; somatic MEN1 alterations also occur in sporadic tumors (~12–35% in reviews) (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 3-4) | PMID 36778668 cited via Open Targets; review DOI: 10.1210/endrev/bnad009 (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 3-4) |
| CDC73 | Hyperparathyroidism-jaw tumor syndrome (HPT-JT); also familial isolated PHPT and parathyroid carcinoma predisposition | Autosomal dominant | Can present with multigland disease, but especially important for carcinoma-risk PHPT; not limited to diffuse hyperplasia | HPT-JT has incomplete penetrance; reported parathyroid carcinoma risk ~20–25%; in a selected high-risk Indian cohort, 4/39 (10.2%) had CDC73 variants; germline CDC73 was the commonest abnormality in atypical parathyroid adenoma and carcinoma cohorts in one study (qadir2024moleculargeneticsin pages 1-3, jha2023molecularandclinical pages 15-16, simonds2020clinicalandmolecular pages 4-6) | Review DOI: 10.1210/endrev/bnad009; cohort DOI: 10.21203/rs.3.rs-5299691/v1 (qadir2024moleculargeneticsin pages 1-3, jha2023molecularandclinical pages 15-16, simonds2020clinicalandmolecular pages 4-6) |
| RET | Multiple endocrine neoplasia type 2A (MEN2A) | Autosomal dominant | Usually not the dominant parathyroid presentation; may cause parathyroid tumors/hyperplasia, often with medullary thyroid carcinoma and pheochromocytoma | Lower penetrance than MEN1; English et al. report MEN2 PHPT ~5–15%; large MEN2A cohort (1085 patients) had only 10 patients initially presenting with PHPT, suggesting low yield of RET testing in isolated PHPT (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 15-16) | Review DOI: 10.1007/s42000-023-00508-9; review DOI: 10.1210/endrev/bnad009 (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 15-16) |
| CDKN1B | MEN4 (MEN1-like syndrome) | Autosomal dominant | Often multiglandular / MEN1-like hereditary PHPT rather than isolated single-gland disease | MEN4 is rarer than MEN1; penetrance for PHPT reported ~75% in review summaries; included on hereditary PHPT testing panels because results affect surgical planning and family testing (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 4-6) | Review DOI: 10.1007/s42000-023-00508-9; ClinVar/Open Targets evidence noted for CDKN1B (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 4-6) |
| CASR | Familial hypocalciuric hypercalcemia type 1 (FHH1); related neonatal severe hyperparathyroidism when biallelic severe loss-of-function | Autosomal dominant for FHH1; biallelic severe forms for NSHPT | Usually not classic hyperplastic PHPT; causes lifelong mild hypercalcemia with inappropriately normal/high PTH and can mimic PHPT; important differential diagnosis to avoid unnecessary PTX | FHH prevalence ~1.3 per 100,000 and accounts for about 2% of apparent PHPT; UCCR <0.01 typical in ~80–95% of FHH; CASR is among the most frequently positive genes in hereditary PHPT testing cohorts (11/19 positives in one UK series were CASR) (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 23-24) | PMIDs in Open Targets include 15572418, 27434672; review DOI: 10.1007/s42000-023-00508-9 (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 23-24) |
| GNA11 | Familial hypocalciuric hypercalcemia type 2 (FHH2) | Autosomal dominant | Usually FHH phenotype rather than true multigland hyperplasia | Included in hereditary hypercalcemia/PHPT differential; like CASR-related FHH, tends to show hypocalciuria and generally benign course rather than surgically correctable hyperplasia (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 15-16, jha2023molecularandclinical pages 23-24) | Review DOI: 10.1210/endrev/bnad009; review DOI: 10.1007/s42000-023-00508-9 (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 15-16, jha2023molecularandclinical pages 23-24) |
| AP2S1 | Familial hypocalciuric hypercalcemia type 3 (FHH3) | Autosomal dominant | Usually FHH mimic, not classic multigland hyperplasia | Nearly all pathogenic variants affect Arg15 in reported series; in a UK hereditary PHPT testing cohort, 1/19 pathogenic findings was AP2S1; clinically relevant because parathyroidectomy usually does not correct FHH (english2024geneticsofhereditary pages 8-9, jha2023molecularandclinical pages 23-24) | Review DOI: 10.1007/s42000-023-00508-9; review DOI: 10.1210/endrev/bnad009 (english2024geneticsofhereditary pages 8-9, jha2023molecularandclinical pages 23-24) |
| GCM2 | Familial isolated hyperparathyroidism (FIHP); activating variants also linked to hereditary PHPT | Usually autosomal dominant with variable/low penetrance | Can be associated with multigland disease / familial hyperplasia-like PHPT, but penetrance is variable and many families remain unexplained | Activating GCM2 variants reported in ~18% of FIHP in some series; among FIHP kindreds pre-screened negative for MEN1/CASR/CDC73, only ~10–20% carry GCM2 variants, leaving ~80–90% unexplained; low penetrance has raised questions about routine panel inclusion in all settings (jha2023molecularandclinical pages 23-24, qadir2024moleculargeneticsin pages 9-11) | PMIDs in Open Targets include 27745835, 39024449, 36653562 (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, jha2023molecularandclinical pages 23-24, qadir2024moleculargeneticsin pages 9-11) |
Table: This table summarizes the main hereditary genes linked to parathyroid hyperplasia, multiglandular disease, or closely related hereditary PHPT phenotypes. It highlights inheritance, the usual parathyroid pattern, and key statistics that help distinguish true multigland disease from mimics such as familial hypocalciuric hypercalcemia.
| Workup component | What to measure/use | Key findings or performance statistics | Notes specific to multigland disease / secondary HPT | Key citations |
|---|---|---|---|---|
| Biochemical diagnosis | Serum total calcium, ionized calcium, intact PTH | PHPT is diagnosed by hypercalcemia with elevated or inappropriately normal PTH; one cohort used serum Ca >2.70 mmol/L and/or ionized Ca >1.28 mmol/L with unsuppressed PTH as diagnostic thresholds | Biochemistry alone cannot reliably distinguish adenoma from hyperplasia/MGD; markedly high calcium and PTH may raise concern for carcinoma rather than benign MGD | (chakrabarty2024imagingrecommendationsfor pages 1-2, chen2023clinicalandgenetic pages 1-2, english2024geneticsofhereditary pages 1-2) |
| Mineral metabolism panel | Serum phosphate, 25-OH vitamin D, renal function | In CKD-related SHPT, progressive hyperphosphatemia and reduced active vitamin D drive hypocalcemia and compensatory parathyroid hyperplasia; vitamin D status is important for surgical outcomes and recurrence risk | Particularly important in SHPT/tHPT to separate CKD-mineral bone disorder from primary disease and to optimize pre-/post-operative management | (pavlidis2023updateonthe pages 1-2, vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2) |
| Urinary calcium assessment | Urinary calcium-to-creatinine clearance ratio (UCCR/UCCR) | Majority of FHH patients have UCCR <0.01; FHH accounts for about 2% of patients initially considered to have PHPT in some series | Essential when apparent PHPT presents with mild hypercalcemia or familial disease; helps avoid unnecessary parathyroidectomy in FHH | (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 23-24) |
| Neck ultrasound | First-line anatomic localization | Widely used first-line tool; pooled sensitivity for US in prior meta-analysis about 80% for PHPT localization | Lower sensitivity in MGD and renal hyperplasia; in renal HPT/hyperplastic glands, sonography sensitivity reported around 62% | (scheepers2023diagnosticperformanceof pages 13-14, vetter2024whatisthe pages 10-12, chakrabarty2024imagingrecommendationsfor media a62b0df1) |
| Sestamibi scintigraphy / SPECT/CT | Functional localization with 99mTc-sestamibi, often with SPECT/CT | Prior meta-analysis pooled sensitivity about 83% for MIBI in PHPT localization | Performance drops in MGD: reported MIBI sensitivity about 44% for MGD; in renal HPT/hyperplastic glands scintigraphy sensitivity around 55% | (scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 14-15, vetter2024whatisthe pages 10-12) |
| 4DCT | Multiphasic CT for localization and MGD prediction | One meta-analysis cited sensitivity 81.0% for 4DCT vs 65.0% for MIBI; MGD sensitivity reported about 60%; 4DCT MGD prediction scores: composite score specificity 72% (>=4), 86% (>=5), 100% (=6), CT-only score specificity 74% (>=3) and 88% (>=4) | Helpful when first-line imaging is negative or recurrent disease is suspected; exposes patients to ionizing radiation; useful for predicting MGD before surgery | (chakrabarty2024imagingrecommendationsfor pages 9-11, scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 14-15) |
| MRI / 4D MRI | Radiation-free localization, dynamic contrast-enhanced protocols | Conventional MRI sensitivity 39.1%-94.3%; 4D MRI sensitivity 55.6%-100%; first-line 4D MRI often 64%-100%; reported MGD sensitivity 67%-100%; one review cited 92% for single-gland disease and 74% for MGD | Attractive in younger patients, recurrent disease, and when radiation avoidance matters; superior to conventional imaging in some reoperative/MGD settings | (chakrabarty2024imagingrecommendationsfor pages 9-11, scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 9-11, scheepers2023diagnosticperformanceof pages 1-2) |
| 18F-FCH PET/CT | High-resolution functional imaging | Reported as superior to ultrasound and MIBI; accepted as an alternative first-line modality in some centers | Useful in difficult localization, persistent/recurrent disease, and MGD; increasingly used before reoperation | (chakrabarty2024imagingrecommendationsfor pages 9-11, pavlidis2023updateonthe pages 1-2, scheepers2023diagnosticperformanceof pages 2-4, chakrabarty2024imagingrecommendationsfor media a62b0df1) |
| PET/MRI | Hybrid metabolic + high-contrast soft tissue imaging | 18F-FCH PET/MRI sensitivity 84.2%-100%; specificity 96.0%-100% in reported studies; described as highest diagnostic accuracy among MRI-based approaches | Particularly useful for MGD, pediatric patients, and complex surgical planning while minimizing radiation | (scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 9-11, chakrabarty2024imagingrecommendationsfor pages 9-11) |
| Intraoperative PTH monitoring | Rapid ioPTH during parathyroidectomy | In PHPT/reoperative disease, PTH <=40 pg/mL or >=50% drop from baseline minimizes persistence risk; Miami criterion (>50% drop at >=10 min) is used in tertiary/renal HPT surgery literature | In SHPT, formal ioPTH criteria are less established because all hyperplastic glands must be removed; nevertheless, intraoperative monitoring may support completeness of resection | (pavlidis2023updateonthe pages 1-2, costea2025tertiaryhyperparathyroidismin pages 10-12, hiramitsu2023treatmentforsecondary pages 1-2) |
| Postoperative surveillance | Serum calcium and PTH follow-up | Six-month calcium >=9.8 mg/dL and PTH >=80 pg/mL indicate higher recurrence risk after PHPT surgery | Four-gland hyperplasia/double adenomas have higher persistence/recurrence risk, so long-term follow-up is especially important | (pavlidis2023updateonthe pages 1-2) |
| Strategy for MGD / renal hyperplasia | Bilateral neck exploration, selective imaging, four-gland assessment | Figure-based management algorithms recommend imaging for planning, then bilateral neck exploration with subtotal or total parathyroidectomy for MGD; in tHPT, 90% have multiglandular disease | In SHPT/tHPT, localization imaging is adjunctive; operative four-gland exploration remains the most reliable strategy because hyperplasia is often diffuse/multiglandular | (vetter2024whatisthe pages 10-12, vetter2024whatisthe pages 1-3, chakrabarty2024imagingrecommendationsfor media 9629bfff) |
Table: This table summarizes the current diagnostic workup for parathyroid hyperplasia and related hyperparathyroid states, including key laboratory tests, localization imaging, intraoperative monitoring, and special considerations for multigland disease and CKD-related secondary/tertiary hyperparathyroidism.
| Context | Treatment / implementation | Real-world use / indication | Key outcomes or statistics | Trial / source |
|---|---|---|---|---|
| PHPT with multigland disease (formerly “hyperplasia”; WHO 2022 favors MGD terminology) | Bilateral neck exploration (BNE) with subtotal or total parathyroidectomy | Preferred operative pathway when multigland disease is suspected/localized poorly; imaging mainly supports planning, but definitive management is surgical exploration | Figure-based algorithm recommends imaging ± parathyroid venous sampling, then BNE followed by subtotal/total parathyroidectomy for MGD; multigland disease/hyperplasia is associated with higher persistence/recurrence risk after surgery than single-gland disease (chakrabarty2024imagingrecommendationsfor media a62b0df1, pavlidis2023updateonthe pages 1-2) | Chakrabarty 2024; Pavlidis 2023 (chakrabarty2024imagingrecommendationsfor media a62b0df1, pavlidis2023updateonthe pages 1-2) |
| PHPT, persistent/recurrent disease risk management | Intraoperative PTH monitoring during parathyroidectomy | Used to reduce risk of persistence in resection for pHPT, including cases with multigland disease | Intraoperative PTH ≤ 40 pg/mL or a ≥50% drop from baseline minimized persistence risk; recurrence risk higher with double adenomas/four-gland hyperplasia; modern recurrence rates reported ~2.5–5% (pavlidis2023updateonthe pages 1-2) | Pavlidis 2023 (pavlidis2023updateonthe pages 1-2) |
| PHPT managed medically when surgery is not performed or delayed | Cinacalcet, denosumab, or combination (plus vitamin D) | Investigated for biochemical control and bone protection in primary hyperparathyroidism; not curative for multigland disease but relevant where surgery is deferred/inappropriate | DENOCINA phase 3 trial enrolled 46 patients; combined arm used denosumab 60 mg every 6 months + cinacalcet 30 mg daily + vitamin D 50 μg daily; endpoints included DXA BMD, serum calcium, PTH, bone turnover markers, nephrolithiasis/nephrocalcinosis imaging outcomes (NCT03027557 chunk 1, NCT03027557 chunk 2, NCT03027557 chunk 3) | NCT03027557 / DENOCINA (NCT03027557 chunk 1, NCT03027557 chunk 2, NCT03027557 chunk 3) |
| CKD-related secondary hyperparathyroidism (SHPT) | Phosphate control: dietary phosphate restriction and phosphate binders | First-line background management to reduce chronic parathyroid stimulation in CKD-mineral bone disorder | Standard therapy in SHPT; used alongside vitamin D analogs and calcimimetics before considering surgery (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3, NCT01421407 chunk 1) | Vetter 2024; Sevva 2024; NCT01421407 background (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3, NCT01421407 chunk 1) |
| CKD-related SHPT | Vitamin D receptor activators/analogs (calcitriol, alfacalcidol/alphacalcidol, doxercalciferol, paricalcitol; others in regional practice) | Common medical therapy for hypocalcemia-driven PTH excess | Recommended pharmacologic option in CKD SHPT; used with phosphate lowering and/or calcimimetics; tertiary HPT review notes they lower PTH, though vascular calcification effects remain debated (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3, costea2025tertiaryhyperparathyroidismin pages 9-10) | Vetter 2024; Sevva 2024; Costea 2025 (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3, costea2025tertiaryhyperparathyroidismin pages 9-10) |
| CKD-related SHPT | Calcimimetics: cinacalcet (oral) | Widely used for refractory biochemical SHPT on dialysis | Background/eligibility in HIFU trial required PTH >800 pg/mL despite ≥3 months cinacalcet >30 mg/day ± vitamin D; cinacalcet also reported to improve endothelial dysfunction/cardiac hypertrophy in hemodialysis patients in reviewed literature (NCT01421407 chunk 1, vetter2024whatisthe pages 17-18) | NCT01421407; Vetter 2024 (NCT01421407 chunk 1, vetter2024whatisthe pages 17-18) |
| CKD-related SHPT | Calcimimetics: etelcalcetide (IV during dialysis) | Real-world dialysis implementation as second-generation calcimimetic | In a 2018–2023 retrospective cohort of 52 dialysis patients, 34/52 (65.4%) received cinacalcet and etelcalcetide; 29/33 (87.9%) treated with etelcalcetide had significant PTH reduction, up to 57% from baseline; none required parathyroidectomy for refractory PTH or drug toxicity in that series (sevva2024pharmaceuticalmanagementof pages 1-2) | Sevva 2024 (sevva2024pharmaceuticalmanagementof pages 1-2) |
| CKD-related SHPT, drug-refractory disease | Parathyroidectomy (subtotal PTX, total PTX with autotransplantation, or total PTX without autotransplantation; sometimes with transcervical thymectomy) | Reserved for refractory SHPT, severe symptoms, or failure/cost issues of medical therapy | Review emphasizes PTx remains one of the most important therapies despite calcimimetics; complete removal of all glands is crucial to prevent persistence/recurrence; PTx associated with improved bone density, fracture risk, survival, and quality of life (hiramitsu2023treatmentforsecondary pages 1-2) | Hiramitsu 2023 (hiramitsu2023treatmentforsecondary pages 1-2) |
| CKD-related SHPT in transplant candidates | Subtotal PTX or total PTX with autotransplantation | Preferred when future kidney transplantation is anticipated | 2024 surgical review recommends subtotal PTX or total PTX with autotransplantation for transplant-eligible patients; total PTX can be considered for non-transplant candidates (vetter2024whatisthe pages 1-3) | Vetter 2024 (vetter2024whatisthe pages 1-3) |
| Post-transplant tertiary hyperparathyroidism (tHPT) | Subtotal parathyroidectomy with four-gland exploration | Favored surgical approach for persistent autonomous post-transplant disease, usually multiglandular | Review states 90% of tHPT patients have multigland disease; subtotal PTX is favored because it has lower hypoparathyroidism risk than total PTX with autotransplantation with similar cure rates (vetter2024whatisthe pages 10-12) | Vetter 2024 (vetter2024whatisthe pages 10-12) |
| Post-transplant tertiary hyperparathyroidism (tHPT) | Timing of parathyroidectomy before vs after transplant | Individualized based on suspected autonomy, graft considerations, and biochemical persistence | If autonomy is suspected, surgery ideally precedes transplantation; if post-transplant surgery is needed, many centers delay until ~1 year; persistent sHPT/tHPT reported to decline from 70% at 1 year to 43% at 2 years post-transplant (vetter2024whatisthe pages 1-3); a meta-analysis of 223 patients found no significant difference between pre- vs post-transplant PTX for follow-up PTH or calcium (vetter2024whatisthe pages 1-3) | Vetter 2024; Karniadakis 2025 abstracted in search results (vetter2024whatisthe pages 1-3) |
| Post-transplant tertiary hyperparathyroidism (tHPT) | Surgery vs cinacalcet | Comparative management for persistent autonomous disease after transplant | Retrospective comparison cited in 2024 review found parathyroidectomy achieved higher PTH normalization and lower graft failure than cinacalcet (9% vs 33% allograft loss) (vetter2024whatisthe pages 10-12) | Vetter 2024 (vetter2024whatisthe pages 10-12) |
| Procedural/ablative alternative for SHPT | High-intensity focused ultrasound (HIFU; TH-One device) | Investigational non-surgical ablation for uncontrolled SHPT in chronic hemodialysis with 1–2 enlarged glands on ultrasound | Randomized open-label trial planned primary endpoint of ≥30% reduction in mean serum iPTH at 6 months and secondary endpoint of achieving KDIGO-range PTH; required uncontrolled disease despite cinacalcet; study was withdrawn with actual enrollment = 0 (NCT01421407 chunk 1) | NCT01421407 (NCT01421407 chunk 1) |
Table: This table summarizes treatment strategies and real-world implementation of therapies for parathyroid hyperplasia across primary multigland disease, CKD-related secondary hyperparathyroidism, and post-transplant tertiary hyperparathyroidism. It highlights surgical standards, medical therapies, response statistics, and relevant clinical trial identifiers.
The 2024 imaging review contains (i) a table comparing imaging modalities and (ii) a management algorithm with a dedicated multigland disease branch supporting bilateral neck exploration with subtotal/total parathyroidectomy (chakrabarty2024imagingrecommendationsfor media 9629bfff, chakrabarty2024imagingrecommendationsfor media a62b0df1).
References
(jha2023molecularandclinical pages 8-9): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.
(vetter2024whatisthe pages 1-3): Diana Vetter and Thomas Schachtner. What is the role of surgery in secondary and tertiary hyperparathyroidism? Advances in Kidney Transplantation [Working Title], Aug 2024. URL: https://doi.org/10.5772/intechopen.1006528, doi:10.5772/intechopen.1006528. This article has 0 citations.
(costea2025tertiaryhyperparathyroidismin pages 4-6): Mirona Costea, D. Tilici, D. Păun, V. Nimigean, S. Paun, and R. Dǎnciulescu-Miulescu. Tertiary hyperparathyroidism in diabetic nephropathy: an underrecognized complication—a narrative review. Biomedicines, Oct 2025. URL: https://doi.org/10.3390/biomedicines13112604, doi:10.3390/biomedicines13112604. This article has 2 citations.
(OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET): Open Targets Query (Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, 37 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(chakrabarty2024imagingrecommendationsfor pages 3-5): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.
(hiramitsu2023treatmentforsecondary pages 1-2): Takahisa Hiramitsu, Yuki Hasegawa, Kenta Futamura, Manabu Okada, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai, Yoshihiro Tominaga, and Toshihiro Ichimori. Treatment for secondary hyperparathyroidism focusing on parathyroidectomy. Frontiers in Endocrinology, Apr 2023. URL: https://doi.org/10.3389/fendo.2023.1169793, doi:10.3389/fendo.2023.1169793. This article has 47 citations.
(vetter2024whatisthe pages 10-12): Diana Vetter and Thomas Schachtner. What is the role of surgery in secondary and tertiary hyperparathyroidism? Advances in Kidney Transplantation [Working Title], Aug 2024. URL: https://doi.org/10.5772/intechopen.1006528, doi:10.5772/intechopen.1006528. This article has 0 citations.
(chakrabarty2024imagingrecommendationsfor pages 1-2): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.
(NCT03027557 chunk 1): Peter Vestergaard. Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.. Peter Vestergaard. 2017. ClinicalTrials.gov Identifier: NCT03027557
(NCT03027557 chunk 3): Peter Vestergaard. Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.. Peter Vestergaard. 2017. ClinicalTrials.gov Identifier: NCT03027557
(NCT01421407 chunk 1): Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism. Theraclion. 2011. ClinicalTrials.gov Identifier: NCT01421407
(pavlidis2023updateonthe pages 1-2): Efstathios T Pavlidis and Theodoros E Pavlidis. Update on the current management of persistent and recurrent primary hyperparathyroidism after parathyroidectomy. World Journal of Clinical Cases, 11:2213-2225, Apr 2023. URL: https://doi.org/10.12998/wjcc.v11.i10.2213, doi:10.12998/wjcc.v11.i10.2213. This article has 23 citations.
(jha2023molecularandclinical pages 7-8): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.
(english2024geneticsofhereditary pages 8-9): Katherine A. English, Kate E. Lines, and Rajesh V. Thakker. Genetics of hereditary forms of primary hyperparathyroidism. Hormones (Athens, Greece), 23:3-14, Dec 2024. URL: https://doi.org/10.1007/s42000-023-00508-9, doi:10.1007/s42000-023-00508-9. This article has 41 citations.
(scheepers2023diagnosticperformanceof pages 13-14): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.
(chen2023clinicalandgenetic pages 1-2): Yingyu Chen, An Song, Min Nie, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, and Xiaoping Xing. Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a chinese cohort. Frontiers in Endocrinology, Jan 2023. URL: https://doi.org/10.3389/fendo.2023.1027598, doi:10.3389/fendo.2023.1027598. This article has 19 citations.
(chen2023clinicalandgenetic pages 6-8): Yingyu Chen, An Song, Min Nie, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, and Xiaoping Xing. Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a chinese cohort. Frontiers in Endocrinology, Jan 2023. URL: https://doi.org/10.3389/fendo.2023.1027598, doi:10.3389/fendo.2023.1027598. This article has 19 citations.
(verdelli2024heterogeneoustranscriptionallandscapes pages 1-2): Chiara Verdelli, Silvia Carrara, Riccardo Maggiore, Paolo Dalino Ciaramella, and Sabrina Corbetta. Heterogeneous transcriptional landscapes in human sporadic parathyroid gland tumors. International Journal of Molecular Sciences, 25:10782, Oct 2024. URL: https://doi.org/10.3390/ijms251910782, doi:10.3390/ijms251910782. This article has 3 citations.
(jha2023molecularandclinical pages 1-2): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.
(english2024geneticsofhereditary pages 1-2): Katherine A. English, Kate E. Lines, and Rajesh V. Thakker. Genetics of hereditary forms of primary hyperparathyroidism. Hormones (Athens, Greece), 23:3-14, Dec 2024. URL: https://doi.org/10.1007/s42000-023-00508-9, doi:10.1007/s42000-023-00508-9. This article has 41 citations.
(jha2023molecularandclinical pages 15-16): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.
(jha2023molecularandclinical pages 23-24): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.
(qadir2024moleculargeneticsin pages 1-3): Ajaz Qadir, Raiz Ahmad Misgar, Ankit Chhabra, Imtiyaz Ahmad Bhat, Mir Iftikhar Bashir, Arshad Iqbal Wani, Munir Ahmad Wani, and Ajaz Ahmad Malik. Molecular genetics in familial primary hyperparathyroidism: a study from northern india. Nov 2024. URL: https://doi.org/10.21203/rs.3.rs-5299691/v1, doi:10.21203/rs.3.rs-5299691/v1.
(roser2023diagnosisandmanagement pages 3-5): Pia Roser, Bianca M Leca, Claudia Coelho, Klaus-Martin Schulte, Jackie Gilbert, Eftychia E Drakou, Christos Kosmas, Ling Ling Chuah, Husam Wassati, Alexander D Miras, James Crane, Simon J B Aylwin, Ashley B Grossman, and Georgios K Dimitriadis. Diagnosis and management of parathyroid carcinoma: a state-of-the-art review. Endocrine-Related Cancer, Apr 2023. URL: https://doi.org/10.1530/erc-22-0287, doi:10.1530/erc-22-0287. This article has 80 citations and is from a domain leading peer-reviewed journal.
(roser2023diagnosisandmanagement pages 7-8): Pia Roser, Bianca M Leca, Claudia Coelho, Klaus-Martin Schulte, Jackie Gilbert, Eftychia E Drakou, Christos Kosmas, Ling Ling Chuah, Husam Wassati, Alexander D Miras, James Crane, Simon J B Aylwin, Ashley B Grossman, and Georgios K Dimitriadis. Diagnosis and management of parathyroid carcinoma: a state-of-the-art review. Endocrine-Related Cancer, Apr 2023. URL: https://doi.org/10.1530/erc-22-0287, doi:10.1530/erc-22-0287. This article has 80 citations and is from a domain leading peer-reviewed journal.
(simonds2020clinicalandmolecular pages 3-4): William F. Simonds. Clinical and molecular genetics of primary hyperparathyroidism. Hormone and Metabolic Research, 52:578-587, Mar 2020. URL: https://doi.org/10.1055/a-1132-6223, doi:10.1055/a-1132-6223. This article has 12 citations and is from a peer-reviewed journal.
(simonds2020clinicalandmolecular pages 4-6): William F. Simonds. Clinical and molecular genetics of primary hyperparathyroidism. Hormone and Metabolic Research, 52:578-587, Mar 2020. URL: https://doi.org/10.1055/a-1132-6223, doi:10.1055/a-1132-6223. This article has 12 citations and is from a peer-reviewed journal.
(qadir2024moleculargeneticsin pages 9-11): Ajaz Qadir, Raiz Ahmad Misgar, Ankit Chhabra, Imtiyaz Ahmad Bhat, Mir Iftikhar Bashir, Arshad Iqbal Wani, Munir Ahmad Wani, and Ajaz Ahmad Malik. Molecular genetics in familial primary hyperparathyroidism: a study from northern india. Nov 2024. URL: https://doi.org/10.21203/rs.3.rs-5299691/v1, doi:10.21203/rs.3.rs-5299691/v1.
(jha2023molecularandclinical pages 11-12): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.
(verdelli2024heterogeneoustranscriptionallandscapes pages 7-9): Chiara Verdelli, Silvia Carrara, Riccardo Maggiore, Paolo Dalino Ciaramella, and Sabrina Corbetta. Heterogeneous transcriptional landscapes in human sporadic parathyroid gland tumors. International Journal of Molecular Sciences, 25:10782, Oct 2024. URL: https://doi.org/10.3390/ijms251910782, doi:10.3390/ijms251910782. This article has 3 citations.
(costea2025tertiaryhyperparathyroidismin pages 2-4): Mirona Costea, D. Tilici, D. Păun, V. Nimigean, S. Paun, and R. Dǎnciulescu-Miulescu. Tertiary hyperparathyroidism in diabetic nephropathy: an underrecognized complication—a narrative review. Biomedicines, Oct 2025. URL: https://doi.org/10.3390/biomedicines13112604, doi:10.3390/biomedicines13112604. This article has 2 citations.
(simonds2020clinicalandmolecular pages 1-3): William F. Simonds. Clinical and molecular genetics of primary hyperparathyroidism. Hormone and Metabolic Research, 52:578-587, Mar 2020. URL: https://doi.org/10.1055/a-1132-6223, doi:10.1055/a-1132-6223. This article has 12 citations and is from a peer-reviewed journal.
(sevva2024pharmaceuticalmanagementof pages 2-3): Christina Sevva, Dimitrios Divanis, Ariti Tsinari, Petros Grammenos, Styliani Laskou, Stylianos Mantalobas, Eleni Paschou, Vasiliki Magra, Periklis Kopsidas, Isaak Kesisoglou, Vassilios Liakopoulos, and Konstantinos Sapalidis. Pharmaceutical management of secondary hyperparathyroidism and the role of surgery: a 5-year retrospective study. Medicina, 60:812, May 2024. URL: https://doi.org/10.3390/medicina60050812, doi:10.3390/medicina60050812. This article has 3 citations.
(jha2023molecularandclinical pages 10-11): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.
(chakrabarty2024imagingrecommendationsfor media a62b0df1): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.
(scheepers2023diagnosticperformanceof pages 14-15): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.
(chakrabarty2024imagingrecommendationsfor pages 9-11): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.
(scheepers2023diagnosticperformanceof pages 9-11): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.
(scheepers2023diagnosticperformanceof pages 1-2): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.
(scheepers2023diagnosticperformanceof pages 2-4): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.
(costea2025tertiaryhyperparathyroidismin pages 10-12): Mirona Costea, D. Tilici, D. Păun, V. Nimigean, S. Paun, and R. Dǎnciulescu-Miulescu. Tertiary hyperparathyroidism in diabetic nephropathy: an underrecognized complication—a narrative review. Biomedicines, Oct 2025. URL: https://doi.org/10.3390/biomedicines13112604, doi:10.3390/biomedicines13112604. This article has 2 citations.
(chakrabarty2024imagingrecommendationsfor media 9629bfff): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.
(NCT03027557 chunk 2): Peter Vestergaard. Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.. Peter Vestergaard. 2017. ClinicalTrials.gov Identifier: NCT03027557
(costea2025tertiaryhyperparathyroidismin pages 9-10): Mirona Costea, D. Tilici, D. Păun, V. Nimigean, S. Paun, and R. Dǎnciulescu-Miulescu. Tertiary hyperparathyroidism in diabetic nephropathy: an underrecognized complication—a narrative review. Biomedicines, Oct 2025. URL: https://doi.org/10.3390/biomedicines13112604, doi:10.3390/biomedicines13112604. This article has 2 citations.
(vetter2024whatisthe pages 17-18): Diana Vetter and Thomas Schachtner. What is the role of surgery in secondary and tertiary hyperparathyroidism? Advances in Kidney Transplantation [Working Title], Aug 2024. URL: https://doi.org/10.5772/intechopen.1006528, doi:10.5772/intechopen.1006528. This article has 0 citations.
(sevva2024pharmaceuticalmanagementof pages 1-2): Christina Sevva, Dimitrios Divanis, Ariti Tsinari, Petros Grammenos, Styliani Laskou, Stylianos Mantalobas, Eleni Paschou, Vasiliki Magra, Periklis Kopsidas, Isaak Kesisoglou, Vassilios Liakopoulos, and Konstantinos Sapalidis. Pharmaceutical management of secondary hyperparathyroidism and the role of surgery: a 5-year retrospective study. Medicina, 60:812, May 2024. URL: https://doi.org/10.3390/medicina60050812, doi:10.3390/medicina60050812. This article has 3 citations.